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Summary 
 
Atherosclerosis is an active and progressive condition where the vascular cell adhesion 
molecules as VCAM-1 play a vital role controlling the recruitment of immune cells within 
the early and advanced plaques. Therefore targeting of VCAM-1 molecules with specific 
contrast agent bears the possibility to monitor the VCAM-1 expression, visualize the 
plaque progression starting at the early alterations, and help to establish early prevention of 
atherosclerosis before the origin of the thrombus formation, of which late recognition leads 
to myocardial infarction. Furthermore noninvasive magnetic resonance imaging (MRI) 
offers the benefit of combining the molecular and anatomic data and would thus enable 
specific detection of VCAM-1 targeted iron oxide contrast agent within inflammatory 
process of atherosclerosis.  
This thesis exactly presents the VCAM-1 concept as a suitable molecular approach 
and the potential of specific ultrasmall superparamagnetic iron oxide (USPIO) conjugated 
to the VCAM-1 binding peptide over unspecific non-targeted USPIO particles for 
evaluation of atherosclerosis. This work firstly demonstrated that selection of VCAM-1 
molecules offers a good and potential strategy for imaging of atherosclerosis, as these 
vascular cell adhesion molecules are highly expressed in the early phase of inflammation 
and also continuously up-regulated within the advanced plaques. Secondly, this thesis 
showed the proof of principle and capability of the newly designed USPIO contrast agent 
conjugated to the specific cyclic peptide for VCAM-1 recognition. The experimental 
studies including ultra-high field MRI enabled further ex vivo and in vivo detection of 
applied USPIO-VCAM-1 particles within the aortic root region of early and advanced 
atherosclerotic plaques of 12 and 30 week old apolipoprotein E deficient (ApoE-/-) mice. 
Using a combination of histology and electron microscopy, this study for the first time 
pointed to distribution of targeted USPIO-VCAM-1 particles within plaque cells 
expressing VCAM-1 not only in luminal regions but also in deeper medial smooth muscle 
cell areas. Hence functionalized USPIO particles targeting VCAM-1 molecules allow 
specific and sensitive detection of early and advanced plaques at the molecular level, 
giving the new possibilities for early recognition of atherosclerotic plaques before the 
appearance of advanced and prone to rupture lesions. In contrast to the functionalized 
USPIO-VCAM-1, utilized non-targeted USPIO particles did not succeed in early plaque 
6 
 
identification limiting visualization of atherosclerosis to advanced forms in atherosclerotic 
ApoE-/- mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Zusammenfassung 
 
Atherosklerose ist eine aktive und progressive Erkrankung, bei der vaskuläre 
Adhäsionsmoleküle wie VCAM-1 eine entscheidende Rolle durch Steuerung der 
Rekrutierung von Immunzellen in den frühen und fortgeschrittenen Plaques spielen. Ein 
zielgerichteter Einsatz von VCAM-1-Molekülen mit spezifischen Kontrastmitteln ist daher 
eine Möglichkeit, die VCAM-1-Expression zu kontrollieren, Plaquewachstum ab einem  
frühen Zeitpunkt zu visualisieren und eine frühe Prävention von Atherosklerose vor 
Beginn der Thrombusbildung zu etablieren. Des Weiteren bietet die nichtinvasive 
Magnetresonanz (MR)-Bildgebung den Vorteil der Kombination molekularer und 
morphologischer Daten. Sie ermöglicht, mithilfe von entwickelten VCAM-1-markierten 
Eisenoxidpartikeln, den spezifischen Nachweis entzündlicher Prozesse während der 
Atherosklerose. 
 Diese Arbeit belegt, dass mit dem VCAM-1-Konzept eine vielversprechende 
Herangehensweise gefunden wurde und dass das, mit spezifischen superparamagnetischen 
Eisenoxid (USPIO) konjugierte VCAM-1-Peptid, gegenüber unspezifischer USPIOs ein 
erhöhtes Potenzial bei der Untersuchung der Atherosklerose in sich trägt. Im ersten Teil 
der Arbeit konnte im Mausmodell gezeigt werden, dass gerade das VCAM-1-Molekül ein 
sinnvoller Ansatzpunkt zur Darstellung und Bildgebung von Atherosklerose ist, da in der 
frühen Phase der Entzündung die vaskulären Zelladhäsionsmoleküle überexprimiert und 
auch kontinuierlich, während der fortschreitenden Plaquebildung, hochreguliert werden. 
Weiterhin beschreibt diese Arbeit die Funktionstüchtigkeit und das Vermögen des neu 
gestalteten USPIO Kontrastmittels mit dem zyklischen Peptid,  in seiner Spezialisierung 
auf die VCAM-1 Erkennung. Experimentelle Studien mit ultra-Hochfeld-MRT 
ermöglichten weitere ex vivo und in vivo Nachweise der eingesetzten USPIO-VCAM-1-
Partikel innerhalb der Region um die Aortenwurzel in frühen und fortgeschrittenen 
atherosklerotischen Plaques von 12 und 30 Wochen alten Apolipoprotein E-defizienten 
(ApoE-/-) Mäusen. Mit ihrer Kombination aus Histologie und Elektronenmikroskopie zeigt 
diese Studie zum ersten Mal die Verteilung von VCAM-1-markierten USPIO Partikeln 
nicht nur in luminalem Bereich der Plaques, sondern auch in tieferen Bereichen der 
medialen Muskelzellen. Dieser spezifische und sensitive Nachweis der frühen und 
fortgeschrittenen Stadien der Plaquebildung bringt auf molekularer Ebene neue 
Möglichkeiten zur Früherkennung von atherosklerotischen Plaques vor dem Entstehen von 
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Rupturen. Im Gegensatz zum USPIO-VCAM-1-Kontrastmittel scheiterten unspezifische 
USPIO Partikel an der Identifikation früher Plaqueformen und begrenzten die 
Visualisierung von Atherosklerose auf fortgeschrittene Stadien in ApoE-/- Mäusen. 
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1. Introduction 
1.1. Pathogenesis of Atherosclerosis 
 
Atherosclerosis is a pathological condition of the arterial wall (Ait-Oufella, Taleb et al. 
2009) and the most common cardiovascular disease (Hansson and Hermansson 2011), 
terminating in myocardial infarction, stroke and peripheral vascular disease (Getz and 
Reardon 2012). The process of atherosclerosis is progressive and may develop unnoticed 
over several years with the origin in early adolescence (Insull 2009). Among the genetic 
and environmental pathogenic aspects, the main risk factor promoting the pathological 
development of atherosclerosis is hypercholesterolemia (Libby 2002; Hansson, Robertson 
et al. 2006; Getz and Reardon 2012). The prolonged period of elevated cholesterol levels 
initiates the inflammatory process within the arterial wall and together with the immune 
cells’ recruitment, chronic plaque growth continues (Hansson and Hermansson 2011). The 
linkage of hypercholesterolemia and inflammation in the pathogenesis of atherosclerosis is 
based on the active presence of vascular cells’ adhesion (VCAM-1) molecules (Iiyama, 
Hajra et al. 1999; Hansson 2001; Huo and Ley 2001; Libby 2002; Hansson and 
Hermansson 2011). These molecules play a pivotal function in the early as well as in the 
advanced phase of atherosclerosis, controlling the onset and continuation of the immune 
cells’ migration into the inflamed vessels. Due to the fact that these molecules appear only 
under inflammatory stimuli and that their expression is enormous during the inflammatory 
cascade of atherosclerosis (Ley and Huo 2001), they could constitute a prime target for 
therapeutic treatment and imaging of cell activation in vivo. Available detection methods 
and monitoring of early and advanced inflammatory processes could further benefit 
researchers and clinicians who search for the best solution to this disease.  
 In accordance with the World Health Organization, within the next few years 
cardiovascular diseases are projected to be the major cause of death not only in the 
developing countries but worldwide (Hansson, Robertson et al. 2006; Hansson and 
Hermansson 2011). Therefore extensive work on the development of molecular and 
cellular techniques as well as of imaging methods is necessary to understand and visualize 
the molecular mechanism of atherosclerosis.  
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1.2. Molecular mechanisms of immune cells’ recruitment within the early 
and advanced atherosclerotic lesions 
 
1.2.1. Fatty streak formation 
 
The origin of the fatty streaks and the inflammatory process starts through the dysfunction 
of endothelial cells at the atheroma-prone branching points further associated with the 
sizeable thickening of intima caused by changes in hemodynamics (Libby, Ridker et al. 
2002; Weber, Zernecke et al. 2008; Insull 2009). Endothelial dysfunction occurs via 
oxidized proinflammatory lipoproteins which provoke the activation of endothelial cells 
within intima (Chi and Melendez 2007; Hansson and Hermansson 2011), release of 
cytokines and expression of adhesion molecules (Choudhury and Fisher 2009; Insull 
2009) such as membrane receptor CD40 (Schonbeck and Libby 2001; Phipps 2008), 
vascular adhesion molecules (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and 
E- and P-selectin (Schonbeck and Libby 2001; Libby, Ridker et al. 2002; Chi and Melendez 
2007). Among the vascular molecules involved in the activation of the vascular and 
immune cells within the arterial wall, VCAM-1 merits notice. The activation pattern of 
these molecules is exceptional and works only under proinflammatory atherosclerotic 
processes (Ley and Huo 2001). VCAM-1 molecules trigger rolling and firm adhesion (Ley 
and Huo 2001) of T-lymphocytes and splenic monocytes (CD14high/Ly6Chigh/CD43low) 
(O'Brien, Allen et al. 1993; Libby 2006; Strauss-Ayali, Conrad et al. 2007; Settles, Etzrodt 
et al. 2011; Quillard and Libby 2012; Robbins, Chudnovskiy et al. 2012) via α4β1 integrin 
binding (Nakashima, Raines et al. 1998; Braun, Pietsch et al. 1999; May, Neumann et al. 
2000; Chi and Melendez 2007; Ley, Miller et al. 2011). Following the firm adhesion, 
leukocytes enter the arterial wall with help of diverse chemokines. One of the crucial 
chemokines involved in leukocytes migration is macrophage chemoattractant protein 
(MCP-1) (Li and Glass 2002; Libby, Ridker et al. 2002; Soufi, Sattler et al. 2002; Chi and 
Melendez 2007). Recruited plaque leukocytes via MCP-1 subsequently secrete platelet-
derived growth factor (PDGF) (Singh, Mengi et al. 2002; Soufi, Sattler et al. 2002), which 
further induces the inflammatory process and encourages the smooth muscle cells (SMCs) 
to participate (Libby 2002; Doran, Meller et al. 2008; Getz and Reardon 2012). In 
response, medial smooth muscle cells mobilize their move towards the intimal region, 
proliferate, produce extracellular matrix, and secrete cytokines which further stimulate 
monocytes, mast cells and lymphocytes towards the arterial wall (Doran, Meller et al. 
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2008; Insull 2009; Quillard and Libby 2012). Like activated endothelial cells, smooth 
muscle cells also express VCAM-1 adhesion molecules (Li, Cybulsky et al. 1993; Braun, 
Pietsch et al. 1999; Doran, Meller et al. 2008). Through the VCAM-1 pathway, these cells 
can interact with endothelial cells and support leukocyte migration within the 
atherosclerotic lesions (Li, Cybulsky et al. 1993; Braun, Pietsch et al. 1999; May, 
Neumann et al. 2000; Doran, Meller et al. 2008).  
 Among recruited immune cells via activated endothelium, monocytes constitute the 
largest immune cell population of the lesions and give rise to macrophages and dendritic 
cells (Weber, Zernecke et al. 2008; Robbins and Swirski 2010; Getz and Reardon 2012; 
Gui, Shimokado et al. 2012; Robbins, Chudnovskiy et al. 2012). Assembled plaque 
macrophages are capable of expressing scavenger receptors such as CD36, CD68, type AI 
and AII, and LOX-1 (Choudhury and Fisher 2009), through which oxidized lipoproteins 
(oxLDLs) are phagocytized (Li and Glass 2002; Ley, Miller et al. 2011; Gui, Shimokado et 
al. 2012). Within macrophages, oxidized LDLs are modified to cholesterol which is further 
deposited in lysosomes and maintained in foamy form (fatty streaks) (Li and Glass 2002; 
Schrijvers, De Meyer et al. 2007; Choudhury and Fisher 2009; Gui, Shimokado et al. 
2012). Besides the macrophage phagocytosis of oxidized lipoproteins, smooth muscle cells 
(SMCs) possess a similar function. SMCs express scavenger receptors, which recognize 
oxLDLs and contribute to foam cells’ creation (fatty streaks) (Schrijvers, De Meyer et al. 
2007; Doran, Meller et al. 2008). Hypercholesterolemia and high lipid deposition within 
activated endothelium and intimal regions as well as the increased expression of vascular 
adhesion molecules are crucial in early recognition of atherosclerosis.   
 
1.2.2. Fibroatheroma formation 
 
During atheroma formation there is progressive chronic accumulation of macrophages and 
other immune cells which expand the plaque size (Gui, Shimokado et al. 2012). Despite the 
role of macrophage foam cells in the control of lipid phagocytosis through scavenger 
receptors in the plaque growth, high content of cholesterol may lead to apoptosis and 
necrosis (Yin, Chaufour et al. 2000; Feng, Yao et al. 2003; Devries-Seimon, Li et al. 2005; 
Schrijvers, De Meyer et al. 2007; Choudhury and Fisher 2009; Gui, Shimokado et al. 
2012). Such a situation appears when huge macrophage deposits of cholesterol accumulate 
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outside in extracellular matrix space (Choudhury and Fisher 2009; Gui, Shimokado et al. 
2012) and this process stimulates macrophage and smooth muscle cells death (Insull 2009). 
Cell necrosis with increasing quantities of extracellular matrix and cholesterol prompts 
further inflammation (Tabas 2005; Insull 2009), which completely changes the 
morphology of the intima (Insull 2009). Lipid rich necrotic cores prevail in the center of 
the intimal lesions. A fibrous cap surrounds the lipid rich necrotic cores, stabilizes the 
plaques and protects them from rupture (Insull 2009). In addition, during the chronic phase 
of inflammation, plaque macrophages are releasing matrix metalloproteinases (MMP) and 
prothrombotic factors which contribute to the destabilization of the plaques’ fibrous cap 
(Libby, Ridker et al. 2002; Singh, Mengi et al. 2002; Gui, Shimokado et al. 2012). Smooth 
muscle cells face the release of MMP and produce instead stabilizing collagen fibrils, 
which protect the fibrous cap from rupture (Singh, Mengi et al. 2002). However there are 
many other factors interfering in the stability of the plaques and thus provoking the 
thrombosis. One such factor is interferon gamma, secreted by activated T cells, which 
accumulates in the vulnerable regions (van der Wal, Becker et al. 1994; Libby, Ridker et 
al. 2002; Singh, Mengi et al. 2002). Interferon gamma hampers the synthesis of collagen in 
smooth muscle cells and seems to participate in the reversal of stable to vulnerable plaques 
(Libby, Ridker et al. 2002; Singh, Mengi et al. 2002). Growth of advanced fibroatheroma 
plaques associated with formation of small microvessels (neovascularization) may promote 
rupture as well (Moreno, Purushothaman et al. 2006; Slevin, Krupinski et al. 2009). All of 
those chronic and complex processes, which involve a variety of different immune cells, 
cytokines, and pro- versus antithrombotic factors in stabilizing and rupturing of the plaques 
are detrimental, and present at each phase of atherosclerotic lesion formation. 
Understanding the whole process of immune cells’ recruitment and early and advanced 
lesion formation is therefore important in order to discover specific molecular targets and 
effective strategies for detection and treatment of this disease.    
 
1.3. Role of VCAM-1 in early and advanced stages of plaque formation 
 
Human as well as murine vascular cells’ adhesion molecule (VCAM-1) is transmembrane 
glycoprotein (CD106) (Cybulsky, Fries et al. 1991; Carlos and Harlan 1994; Huo and Ley 
2001). It has been shown that mouse VCAM-1 represents 75% homology to human 
VCAM-1 molecules (Hession, Moy et al. 1992). VCAM-1 is expressed within activated 
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endothelium (Cybulsky and Gimbrone 1991; Ley and Huo 2001; Libby 2006), smooth 
muscle cells (O'Brien, Allen et al. 1993; Braun, Pietsch et al. 1999), and macrophages 
(Libby and Li 1993; O'Brien, Allen et al. 1993) over the inflammatory atherosclerotic 
period but also within Kupffer cells (van Oosten, van de Bilt et al. 1995), dendritic cells 
(Libby and Li 1993; Balogh, Aydar et al. 2002), activated neurons (Birdsall, Lane et al. 
1992), and fibroblasts (Chen, Chen et al. 2005). VCAM-1, briefly mentioned in chapter: 
1.2.1. Fatty streak formation), appears to be important and compelling in the early phase of 
leukocytes’ adhesion to endothelium at atheroma-prone sites. In contrast to E- and P-
Selectins which capture and mediate rolling of leukocytes at the sites of activated 
endothelium (Huo and Ley 2001; Blankenberg, Barbaux et al. 2003), VCAM-1 is 
responsible for the adhesion and arrest of white blood cells (Nakashima, Raines et al. 
1998; Ley and Huo 2001), especially monocytes and T lymphocytes (Libby 2006), via 
interaction with α4β1 complex promoting the occurrence of these immune cells in the 
evolving young plaques (Nakashima, Raines et al. 1998; Braun, Pietsch et al. 1999; May, 
Neumann et al. 2000; Huo and Ley 2001; Chi and Melendez 2007; Ley, Miller et al. 2011) 
(Figure 1.1). The endothelial VCAM-1 activation initiates the inflammation. The process 
of VCAM-1 activation occurs via nuclear factor-kB (NF-kB) (Blankenberg, Barbaux et al. 
2003; Libby 2006), in response to endothelial cytokine release, and might be influenced by 
an atherogenic diet and oxidized lipoproteins which accumulate within the intima of the 
arterial wall (Iiyama, Hajra et al. 1999; Huo and Ley 2001; Libby 2002; Libby 2006; Chi 
and Melendez 2007). It has been previously published (Nakashima, Raines et al. 1998; 
Cybulsky, Iiyama et al. 2001) that VCAM-1 expression begins prior to leukocytes adhesion 
in cholesterol-fed animal models, giving evidence that cholesterol might induce VCAM-1 
expression pattern (Iiyama, Hajra et al. 1999; Huo and Ley 2001; Libby 2002). It has been 
further reported that besides endothelial cells, VCAM-1 molecules appear on intimal 
smooth muscle cells within the atherosclerotic lesions of human (O'Brien, Allen et al. 
1993; O'Brien, McDonald et al. 1996) and of apolipoprotein E deficient (ApoE-/-) mice 
(Braun, Pietsch et al. 1999), leading to the premise that VCAM-1 expression within 
smooth muscle cells may support leukocytes’ transmigration within early and advanced 
lesions (Libby and Li 1993; May, Neumann et al. 2000; Huo and Ley 2001; Doran, Meller 
et al. 2008). It has also been observed that during leukocytes’ adhesion associated with 
VCAM-1 mechanism, medial smooth muscle cells also express VCAM-1 molecules 
(Braun, Pietsch et al. 1999). Besides the crucial role of these molecules in the early 
lesions, VCAM-1 also plays an important role in advanced fibroatheroma plaques, 
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controlling enhanced recruitment of monocytes to impaired arteries from adventitia, and 
also participating in the neointimal smooth muscle cell proliferation (O'Brien, Allen et al. 
1993; O'Brien, McDonald et al. 1996; Huo and Ley 2001; Ley and Huo 2001).  
 
    
Figure 1.1. VCAM-1 mediated leukocyte adhesion on the activated endothelium at the 
atheroma-prone sites. P- Selectins capture and induce leukocytes’ rolling on endothelium via 
leukocyte ligand (PSGL-1). In consequence, VCAM-1 molecules cause further adhesion and arrest the 
leukocytes. Upon arrest, VCAM-1 molecules linked to leukocyte ligands (α4β1) stabilize the adhesion 
and trigger transmigration. PSGL-1 is the P-selectin glycoprotein ligand-1, α4β1 is an integrin termed 
very late antigen 4, modified from (Schnoor and Parkos 2008). 
 
1.4. Role of α4β1as a co-receptor of VCAM-1  
 
Ligand α4β1 complex, presented on the surface of leukocytes such as monocytes, T 
lymphocytes, eosinophils, and basophils (Cybulsky, Fries et al. 1991; Li, Cybulsky et al. 
1993; Carlos and Harlan 1994; May, Neumann et al. 2000; Ley and Huo 2001), identifies 
VCAM-1 molecules with the high specificity and due to that plays an important role in 
leukocytes recruitment. Thus the α4β1 complex and its active binding sites could serve as a 
therapeutic target for recognition of VCAM-1 molecules (You, Maxwell et al. 2002). 
Knowledge of the mechanism of the α4β1 binding is necessary to design either therapeutic 
pharmacological inhibitors that would block VCAM-1/α4β1 interaction or small 
peptides/antibodies that could on the one side enable inhibition and on the other side detect 
inflammation (You, Maxwell et al. 2002). Human and murine α4β1integrin is a 
transmembrane glycoprotein and consists of α4 (CD49d) chain and β1 (CD29) chain 
(Carlos and Harlan 1994; Huo and Ley 2001). It has been shown that both of the chains 
participate actively in binding to VCAM-1 (Hynes 1992; Humphries, Sheridan et al. 
1995). Thus design of specific drugs or peptides having the α4β1active binding sites for 
VCAM-1 recognition would have unprecedented perspective for targeting and monitoring 
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VCAM-1 expression in the inflammatory process of atherosclerosis and further would help 
to inhibit this chronic condition.   
 
1.5. Mouse model of atherosclerosis 
 
Clinical and experimental surveillances of atherosclerosis simultaneously with molecular 
and cellular investigation of the plaque formation require animal models. Examinations of 
human atherosclerotic lesions are interfered with due to the limitations in noninvasive 
identifications of molecular processes (Virmani, Kolodgie et al. 2000; Corti and Fuster 
2011). There is confined knowledge of human atherosclerotic plaque formation and this 
knowledge is mainly based on carotid arteries studies or luminal stenosis (Insull 2009; 
Libby, DiCarli et al. 2010). Experimental studies in animal models, especially in 
genetically modified mice, have elucidated the enormous role of innate and adaptive 
immune system and lipid metabolism in the regulation of lesion development (Insull 
2009). Therefore studies utilizing animal models help to understand the biological and 
pathophysiological mechanism of plaque formation (Getz and Reardon 2012). Moreover 
experimental animals provide excellent in vivo possibilities to support and prove ex vivo 
cell culture studies and lead to the next step of cardiovascular imaging and treatment of 
atherosclerosis (Daugherty 2002; Meir and Leitersdorf 2004; Vilahur, Padro et al. 2011). 
One of the most widely available and widely used models suitable for human translation 
referring to plaque composition is the transgenic mouse model (Meir and Leitersdorf 2004; 
Pendse, Arbones-Mainar et al. 2009; Getz and Reardon 2012). These genetically 
backcrossed mice with changed expression profile of specific atheroma-prone genes vastly 
increased knowledge of the molecular mechanism involved in atherosclerosis (Daugherty 
2002; Zaragoza, Gomez-Guerrero et al. 2011). The advantage of using a transgenic mouse 
model is easy handling and breeding, and relatively low maintenance costs (Getz and 
Reardon 2012). Among common experimental models, Apoliporotein E deficient mice 
(ApoE-/-) are generally an excellent model for studying atherosclerosis due to prompt and 
spontaneous development of plaques (Nakashima, Plump et al. 1994; Reddick, Zhang et al. 
1994; Meir and Leitersdorf 2004; Hansson, Robertson et al. 2006; Pendse, Arbones-
Mainar et al. 2009; Zaragoza, Gomez-Guerrero et al. 2011). For instance studies affecting 
ApoE -/- mice enabled the discovery of the mechanism of vascular adhesion mediated 
leukocyte transmigration (Dong, Brown et al. 2000) and the important role of matrix 
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metalloproteinase-1 (MMP-1) in advanced plaques (Lemaitre, O'Byrne et al. 2001). 
Apolipoprotein E deficient mice (ApoE -/-) fed a high fat diet are characterized by the 
elevated cholesterol plasma level (Plump, Smith et al. 1992; Reddick, Zhang et al. 1994; 
Meir and Leitersdorf 2004; Getz and Reardon 2012). Triggered by the high fat diet, 
monocyte adhesion occurs early in ApoE-/- mice and progresses to accelerated fatty streak 
formation. The fatty streaks initially emerge within the ascending aorta including the aortic 
root, aortic arch, and the right carotid artery (Nakashima, Plump et al. 1994) and progress 
to fibrous (advanced) plaques due to the increased recruitment of immune cells. These 
mice also develop small plaques in the descending abdominal aorta (Nakashima, Plump et 
al. 1994). The advanced plaques of older ApoE-/- mice are complex and composed of the 
fibrous cap and the necrotic core. The fibrous cap which stabilizes the plaques is occupied 
by foamy macrophages and smooth muscle cells. The necrotic core together with the 
apoptotic cells dominates the center of the plaque and is surrounded by the fibrous cap 
(Nakashima, Plump et al. 1994; Nakashima, Raines et al. 1998).  
 Besides the studies of molecular mechanism of atherosclerosis using ApoE-/- mice, 
this model is commonly utilized to examine noninvasive changes of the plaque size (Meir 
and Leitersdorf 2004; Herold, Wellen et al. 2009), to characterize and target the various 
cells participating in the initiation and chronic progression of atherosclerosis (Jaffer and 
Weissleder 2004; Libby, Nahrendorf et al. 2010; Quillard and Libby 2012).  
 
1.6. Visualization of atherosclerosis 
 
Discovery of molecular biological processes involved in pathogenesis of chronic 
inflammatory condition such as atherosclerosis allows a thorough recognition and 
estimation of this disease (Choudhury and Fisher 2009). The growth of this experimental 
molecular field, its comprehensive knowledge of genes and proteins associated with 
atherosclerosis and the need for preclinical and clinical translation in order to visualize this 
inflammatory process in vivo, has resulted in the development of the atherosclerotic 
molecular imaging techniques (Chen and Wu 2011; Grenier and Brader 2011). This 
expanding field (Jaffer and Weissleder 2004) entails further the development of diverse 
noninvasive imaging modalities (1.6.1. Molecular magnetic resonance imaging modality) 
and highly refined contrast agents (1.6.3. Contrast agents) (Choudhury and Fisher 2009; 
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McAteer, Akhtar et al. 2010; Chen and Wu 2011). Besides present clinical trials 
approaching imaging of plaque size (Toussaint, LaMuraglia et al. 1996; Yuan, Beach et al. 
1998; Corti, Fuster et al. 2001; Shaw 2009; Libby, DiCarli et al. 2010; Corti and Fuster 
2011), advances in the preclinical molecular imaging field intensify understanding and 
monitoring of biological processes involved in plaque formation through the early fatty 
streaks, advanced to ruptured plaques (Jaffer, Libby et al. 2006; Shaw 2009; Libby, 
DiCarli et al. 2010). This discipline may further contribute to early detection of high risk 
lesions prior to symptoms arising, giving new possibilities for better designed diagnoses 
and treatment focused on molecular atherosclerotic therapies (Jaffer, Libby et al. 2006; 
Thorek, Chen et al. 2006; Saraste, Nekolla et al. 2009; Shaw 2009).  
 Because the aim of molecular imaging approaches is to visualize the atherosclerotic 
process at the cellular and molecular level (Weissleder and Mahmood 2001), properly 
designed cellular and molecular targets associated with the highly refined contrast agents 
are needed (Choudhury and Fisher 2009; McAteer, Akhtar et al. 2010; Chen and Wu 2011; 
Corti and Fuster 2011; Grenier and Brader 2011). Possible contrast agents might 
approach the cells or biomolecules involved in atherosclerosis through cellular (non-
targeted) or molecular (targeted) mechanism (Grenier and Brader 2011). The existing non-
targeted contrast agents focus on detection of advanced atherosclerotic plaques and enable 
delivery of these imaging agents to cells owing to phagocytic properties. Targeted contrast 
agents allow to address for instance proteins within the intracellular and extracellular cells’ 
compartments at molecular level (Jaffer, Libby et al. 2006; Thorek, Chen et al. 2006; Chen 
and Wu 2011). The targeted contrast agents may further help to illuminate the very early 
changes before the onset of the plaque growth as well as to help to distinguish the 
molecular pattern at the stable to ruptured plaques (Jaffer, Libby et al. 2006; Thorek, Chen 
et al. 2006; Chen and Wu 2011; Quillard and Libby 2012). The concept and examples of 
cellular (non-targeted) and molecular (targeted) approaches will be presented in the 
chapter: (1.6.5. Molecular targets for MR Imaging). 
   
1.6.1. Molecular magnetic resonance imaging modality 
 
At present, imaging technologies lean on diverse modalities including x-ray computed 
tomography (CT), positron emission tomography (PET), single-photon emission computed 
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tomography (SPECT), intravascular ultrasound (IVUS) and magnetic resonance imaging 
(MRI) which visualize human atherosclerotic plaques (Corti, Fuster et al. 2001; 
Choudhury and Fisher 2009; McAteer, Akhtar et al. 2010; Chen and Wu 2011; Tardif, 
Lesage et al. 2011). Besides the highlighted imaging modalities, which enable assessment 
of the narrowing of the lumen (stenosis) and the plaque composition, the preclinical animal 
studies utilizing bioluminescence imaging (BLI), fluorescence imaging (FI), ultrasound, 
small animal MRI, micro-positron emission tomography (micro-PET), or micro–single 
photon emission computed tomography (microSPECT) help to image the atherosclerotic 
processes at molecular and cellular level (Chen and Wu 2011). Among these diverse 
approaches magnetic resonance imaging (MRI) has established itself as an outstanding 
modality for noninvasive cardiovascular disease detection (Corti, Fuster et al. 2001; Corti 
and Fuster 2011). In contrast to other techniques, MRI is capable of combining high 
spatial resolution (Quillard and Libby 2012) and excellent soft tissue contrast with high 
signal to noise ratio (Corti, Fuster et al. 2001; Choudhury and Fisher 2009; McAteer, 
Akhtar et al. 2010). Further it provides functional data including information about density, 
distribution, and biochemical contrast variation within the imaged tissue (Pintaske, Muller-
Bierl et al. 2006; Sanz and Fayad 2008; Choudhury and Fisher 2009; Chen, Cormode et 
al. 2010; McAteer, Akhtar et al. 2010; Chen and Wu 2011; Corti and Fuster 2011; Tardif, 
Lesage et al. 2011). This noninvasive and nonionizing technique safely allows three 
dimensional data acquisition without radiation exposure which makes it suitable for 
monitoring of patients over time (Corti, Fuster et al. 2001; Sanz and Fayad 2008; 
McAteer, Akhtar et al. 2010; Hahn, Singh et al. 2011; Tardif, Lesage et al. 2011). Beyond 
magnificent spatial resolution, one disadvantage of MRI is its low sensitivity (Choudhury 
and Fisher 2009; Chen, Cormode et al. 2010; McAteer, Akhtar et al. 2010). This difficulty 
can however be overcome by the use of cellular and molecular contrast agents (Choudhury 
and Fisher 2009; McAteer, Akhtar et al. 2010; Tardif, Lesage et al. 2011). Thus molecular 
MR imaging offers the benefit of combining molecular and anatomic information within an 
MR image (Jaffer and Weissleder 2004; Chen and Wu 2011; Tardif, Lesage et al. 2011).  
 In the field of magnetic resonance (MR) imaging hydrogen nuclei are preferably 
used (Chen and Wu 2011) due to their high magnetic sensitivity and the high abundance in 
the form of water molecules within the mammalian tissues. The contrast within the imaged 
mammalian tissues is characterized by two relaxation processes: longitudinal T1 relaxation 
and transverse T2/T2* relaxation time (Klug, Kampf et al. 2010).  
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1.6.2. Contrast mechanism of Spin Echo and Gradient Echo Development 
 
Acquisition of MR images does involve so called sequences, which enable the 
measurement of either T1 or T2 relaxation time and thus vary the image contrast within the 
measured objects. By suitable selection of parameters such as echo time (TE), repetition 
time (TR) and flip angle of the radiofrequency (RF) pulses, high resolution images can be 
obtained within a short imaging time, and changes of the relaxation times before and after 
application of contrast agents can be detected. Two main types of sequences are commonly 
used in MR imaging: spin echo and gradient echo sequences. 
 
1.6.2.1. Spin Echo sequence  
 
Spin echo sequences are based on the application of one 90o and several subsequent 180o 
degrees radiofrequency (RF) pulses. Amongst applied 180o degree pulses the spin echos 
are measured. Application of the first 90o degree pulse brings the magnetization into the 
transverse plane and generates the signal which then decays due to dephasing of the spins. 
This signal loss is considered as T2* decay. The application of a 180o degree pulse brings 
the magnetization in phase and the signal, now defined as T2, is obtained in the form of 
echos (Figure 1.2). Spin echo contrast is based on a combination of T1 and T2 relaxation 
time which can be defined by changing the parameters such as TE and TR. For instance, a 
long TE results in T2-weighted images, whereas short TR increases T1 contrast. By these 
mechanisms, the effects of contrast agent application like gadolinium agents or iron oxide 
contrast agents can be visualized in ex vivo or in vivo conditions (Blackwell, Cranney et al. 
1992; Weishaupt, Kochli et al. 2006; Schroder and Faber 2011). 
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Figure 1.2. Generation of spin echo decay. The 90
o
 degree pulse brings the magnetization into the 
transverse plane and generates the signal which decays  exponentially due to dephasing of the spins. 
180
o
 degree pulse brings the magnetization in phase and the signal, obtained in the form of echo, 
decays after application of subsequent 180
o 
pulses. This signal loss is considered as T2 effect. 
 
1.6.2.2. Gradient Echo sequence 
 
Gradient echo sequences consist of a radiofrequency (RF) pulse of a small flip angle. 
Application of the RF pulse brings the magnetization intentionally only partly towards the 
transverse plane and generates the signal which decays due to dephasing of the spins. This 
signal loss is due to T2*, a combination of the T2 relaxation time and magnetic field 
inhomogeneity (Figure 1.3). To measure T2*, one or more gradient echos are usually 
applied. Contrast T2*-weighted images require only single echo imaging, whilst T2* 
mapping entails more. Moreover with applied T2* contrast agents, it is recommended to 
use short echo times as the effect is so strong that the contrast is generated nearly 
immediately. The appropriate adjustment of TE and flip angle can detect the alteration 
within the sample or tissue associated with the contrast agent application, especially with 
iron oxide contrast agents (Blackwell, Cranney et al. 1992; Weishaupt, Kochli et al. 2006; 
Schroder and Faber 2011).  
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Figure 1.3. Generation of gradient echo decay. Application of an RF pulse of small flip angle 
brings the magnetization partly towards the transverse plane and generate the signal which decays 
according to the dephasing of the magnetization. This signal loss is considered as T2* effect. 
 
1.6.3. Contrast agents 
 
The T1 and T2 relaxation mechanisms enable displaying of diverse contrasts within the 
MR image, and owing to that provide morphological information of measured tissues 
(Klug, Kampf et al. 2010). The effect of T1 and T2 can be altered by various contrast 
agents (Tang, Muller et al. 2009; Chen, Cormode et al. 2010; Klug, Kampf et al. 2010; 
Chen and Wu 2011), which increase the MR sensitivity effect and therefore enhance the 
image contrast (Klug, Kampf et al. 2010). Moreover, use of contrast agents enables the 
identification of diseased regions at cellular and molecular level (Weissleder and 
Mahmood 2001; McAteer, Akhtar et al. 2010). This information might be important for 
effective disease recognition, diagnosis and even more for designing new drug therapies 
(Jaffer, Libby et al. 2006). There are two kinds of contrast agents for MR imaging, grouped 
as positive and negative contrast agents. The positive contrast agents compose of 
gadolinium chelates (Gd-DTPA), whereas the negative contrast agents consist of 
superparamagnetic iron oxide particles (McAteer, Akhtar et al. 2010; Schroder and Faber 
2011). In addition, MR sequence parameters can be chosen in such a way, that iron oxide 
particles can also be used as positive contrast agents (Dahnke, Liu et al. 2008; Korosoglou, 
Weiss et al. 2008). Gadolinium chelates shorten T1 relaxation time of water protons (spins) 
and due to that enhance the image contrast by generating positive signal, which appears 
bright on T1-weighted images (Choudhury and Fisher 2009; Saraste, Nekolla et al. 2009; 
McAteer, Akhtar et al. 2010). Nevertheless, their use in molecular imaging might be not 
sufficient due to their low MR sensitivity effect (Bulte and Kraitchman 2004; Debbage 
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and Jaschke 2008; McAteer, Akhtar et al. 2010). In contrast to gadolinium agents, 
superparamagnetic iron oxide agents have gained more attention in the field of molecular 
imaging, because of their strong effect. These particles shorten T2 and T2* relaxation time 
of water protons (spins) and due to this phenomenon, they enhance the image contrast by 
generating a signal loss which appears dark on T2- and T2*-weighted images. This 
characteristic signal loss pattern is called the blooming effect (McAteer, Akhtar et al. 
2010). Owing to their strong effect on MR sensitivity, superparamagnetic iron oxide 
nanoparticles have already been successfully applied in preclinical imaging and have 
further shown the usefulness in clinical practice (Weissleder, Elizondo et al. 1990; Kooi, 
Cappendijk et al. 2003; Bulte and Kraitchman 2004; Corot, Robert et al. 2006; Sosnovik  
and Caravan 2009). Researchers have considered iron oxide particles as a suitable tool for 
cellular and molecular visualization of pathological conditions such as inflammation, 
atherosclerosis, myocarditis, metastatic lymph nodes, musculoskeletal diseases or 
degenerative disorders such as multiple sclerosis or Alzheimer’s disease (Hauger, 
Delalande et al. 2000; Schmitz, Coupland et al. 2000; Litovsky, Madjid et al. 2003; Bulte 
and Kraitchman 2004; Choi, Moon et al. 2007; Klug, Kampf et al. 2009; Reiner, Lutz et al. 
2009; Sigovan, Boussel et al. 2009; Tang, Muller et al. 2009; Sigovan, Bessaad et al. 
2010; Weinstein, Varallyay et al. 2010; Grenier and Brader 2011; Leuschner and 
Nahrendorf 2011; Moon, Park et al. 2012). 
 
1.6.4. Properties of iron oxide particles  
 
Superparamagnetic iron oxide nanoparticles consist of a maghemite or magnetite (Fe2O3, 
Fe3O4) core and a polymer coating such as dextran, carboxydextran, or polyethyleneglycol 
(PEG) (Morales, Veintemillas-Verdaguer et al. 1999; Corot, Robert et al. 2006; Thorek, 
Chen et al. 2006; Laurent, Forge et al. 2008; Amstad, Zurcher et al. 2009; Weinstein, 
Varallyay et al. 2010). The coating not only stabilizes the iron oxide particles, but may also 
strongly influence the phagocytic activity of immune cells (Corot, Robert et al. 2006; 
Thorek, Chen et al. 2006; Lipinski, Briley-Saebo et al. 2008; Chen, Cormode et al. 2010; 
Weinstein, Varallyay et al. 2010), and may further serve as a link for conjugation of the 
targeted approaches (Bulte and Kraitchman 2004; Corot, Robert et al. 2006; Thorek, Chen 
et al. 2006). Besides the common dextran and PEG coating, iron particles might also be 
placed in liposomes or high-density lipoproteins (HDL), as they were previously 
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demonstrated, to enhance the macrophage phagocytic uptake (Cormode, Skajaa et al. 
2008; Meincke, Schlorf et al. 2008; Chen, Cormode et al. 2010). The iron oxide particles 
possess strong superparamagnetic characteristics (Thorek, Chen et al. 2006), which are 
determined by their small size iron core ranging from 4 to 10 nm (Corot, Robert et al. 
2006) due to that these particles own a strong effect on MR sensitivity. Besides their strong 
superparamagnetic characteristics, iron oxide particles are biocompatible and 
biodegradable (Corot, Robert et al. 2006; Thorek, Chen et al. 2006). They do not possess 
any toxicity, and due to this they can be safely used for in vivo application (Corot, Robert 
et al. 2006; Thorek, Chen et al. 2006; Lipinski, Briley-Saebo et al. 2008; Chen, Cormode 
et al. 2010). Referring to the size of the iron particles, there are ultrasmall 
superparamagnetic particles of iron oxide (USPIO) with the diameter of 20-40 nm, cross 
linked iron oxide particles (CLIO) with the diameter of 30-60 nm, superparamagnetic 
particles of iron oxide (SPIO) with the diameter of 60-250 nm, and micrometer sized 
particles of iron oxide (MPIO) with the diameter of 0.9-8 µm (McAteer, Akhtar et al. 
2010). In the cardiovascular preclinical imaging field, it has been shown that the large 
sized iron oxide particles such as SPIO or MPIO (Schmitz, Coupland et al. 2000; Bulte and 
Kraitchman 2004; Shapiro, Skrtic et al. 2005; Corot, Robert et al. 2006; McAteer, Akhtar 
et al. 2010), when injected into the blood stream of animals, were promptly recognized by 
immune cells in the spleen, bone marrow, liver, or lymph nodes, resulting in a very fast 
half-life time of about 2 to 5 minutes (Oude Engberink, van der Pol et al. 2007; Tang, 
Muller et al. 2009; McAteer, Akhtar et al. 2010; Weinstein, Varallyay et al. 2010). In 
clinical use, the aspect of the rapid clearance of contrast agents is of great consideration, 
however such a short half-life time of 2 to 5 minutes is not suitable for visualization of the 
chronic inflammatory process of atherosclerosis. Too short a circulation time hampers the 
cellular access of large nanoparticles to the regions of interests such as of atherosclerotic 
plaques. In contrast, small sized iron oxide particles such as USPIOs are a better approach 
by having a longer half-life time (Corot, Robert et al. 2006; Weinstein, Varallyay et al. 
2010; Chen and Wu 2011; Grenier and Brader 2011) than SPIOs or MPIOs. That is why, 
they can circulate in the blood stream for longer, allowing a thriving cells’ uptake within 
the inflamed atherosclerotic tissues (Kooi, Cappendijk et al. 2003; Modo, Hoehn et al. 
2005; Corot, Robert et al. 2006; Tang, Muller et al. 2009; Weinstein, Varallyay et al. 
2010). The cellular transport of USPIOs particles, which is based on phagocytosis is not 
well known (Corot, Robert et al. 2006; Grenier and Brader 2011). There are three theories 
of how the iron oxide particles reach the atherosclerotic lesions. The first mechanism refers 
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to USPIO transcytosis through endothelium followed by cellular phagocytosis from 
resident macrophages via scavenger receptors SR-A (Bulte and Kraitchman 2004; Corot, 
Robert et al. 2006; Tang, Muller et al. 2009). The second mechanism refers to cellular 
uptake by blood monocytes, which then transfer the iron particles to the inflamed plaques 
(Corot, Robert et al. 2006). The third mechanism, which is less probable, depicts the 
USPIO uptake and transport to advanced plaques via adventitia (Corot, Robert et al. 2006). 
This issue is still under further investigation in order to find the answer to the question of 
the iron uptake mechanism (Corot, Robert et al. 2006). As USPIOs were mainly designed 
for cellular non-targeted imaging, and as this approach is nonspecific, it may lead to 
challenges related to extremely high injection doses for MR detection of inflamed 
atherosclerotic tissues. Another issue of using non-targeted iron oxide particles is that they 
allow detection at the very late stage of advanced to ruptured atherosclerotic plaques. Thus 
targeted iron oxide contrast agents are the better platform for cardiovascular imaging, 
allowing early and sensitive detection of molecular processes before the appearance of 
advanced atherosclerotic lesions.  
 
1.6.5. Molecular targets for MR Imaging  
 
There are several molecules and immune cells (described in the chapter 1.2.1. Fatty streak 
formation and 1.2.2. Fibroatheroma formation), which actively participate in the plaque 
formation and therefore could become interesting imaging targets. One of the proposed 
concepts for plaque imaging was phagocytic activity of macrophages (Ruehm, Corot et al. 
2001), oxidized lipoproteins (oxLDLs) (Tsimikas and Shaw 2002), or reactive oxygen 
species (ROS) production (Nahrendorf, Sosnovik et al. 2008). The macrophage 
phagocytosis or oxLDL molecules, recognized by macrophage scavenger receptors, have 
potential as molecular imaging targets due to the fact that these processes are accelerated in 
atherosclerosis and that monocytes and macrophages constitute the largest population of 
cells within the plaques (Weber, Zernecke et al. 2008; Saraste, Nekolla et al. 2009; Shaw 
2009; Gui, Shimokado et al. 2012). There have been previously published studies targeting 
either macrophages and their scavenger receptors or oxidized lipoproteins (oxLDLs) in 
order to detect advanced plaques by optical, PET, and MR imaging modalities (Tsimikas, 
Shortal et al. 2000; Nahrendorf, Zhang et al. 2008; Sigovan, Bessaad et al. 2010; Quillard 
and Libby 2012). For instance, agents linked with gadolinium have been introduced to 
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target the macrophage scavenger receptors and to visualize atherosclerosis in mice 
(Amirbekian, Lipinski et al. 2007; Quillard and Libby 2012). To further visualize murine 
advanced plaques, macrophage CD68 receptor has also been targeted by use of antibody 
conjugated to iodine 124I (Quillard and Libby 2012; Temma and Saji 2012). ROS 
production was also approached by targeting myeloperoxidases (MPO) in rabbit 
atherosclerotic plaques by targeted-gadolinium (Ronald, Chen et al. 2009; Quillard and 
Libby 2012). The successful experimental detection of macrophage phagocytosis with iron 
oxide nanoparticles or radiolabeled agents in the atherosclerotic animal model was also 
implemented in clinics (Kooi, Cappendijk et al. 2003; Pedersen, Graebe et al. 2010). 
Another example of molecular targets are matrix metalloproteinases (MMP) which are 
secreted by active macrophages (Schafers, Riemann et al. 2004; Lancelot, Amirbekian et 
al. 2008; Quillard and Libby 2012). For instance gadolinium and iron oxide contrast 
agents with MMP-2 and MMP-9 fragments, designed for optical or magnetic resonance 
imaging, were used as smart probes in order to visualize advanced plaques (Quillard and 
Libby 2012). Imaging of advanced plaques also involves phosphatidylserine, approached 
by annexin V, presented on death macrophages in the necrotic core of formed plaques 
(Kietselaer, Reutelingsperger et al. 2004; Schellenberger, Sosnovik et al. 2004; Jaffer, 
Libby et al. 2006; Sarai, Hartung et al. 2007; Quillard and Libby 2012). For example in 
atherosclerotic mice, linkage of annexin V to gadolinium and SPIO particles enabled MR 
detection of plaques within abdominal aorta (Quillard and Libby 2012). Integrins αvβ3, 
which are expressed on new plaque microvessels, have also been proposed as a good 
imaging target (Quillard and Libby 2012). It has been published that αvβ3 integrin binding 
RDG peptide linked to gadolinium nanoparticles enhanced the possibility to visualize 
advanced plaques in abdominal aorta of atherosclerotic mice and rabbits (Winter, 
Morawski et al. 2003; Burtea, Laurent et al. 2008; Quillard and Libby 2012). Activated 
platelets, which contribute to thrombus formation at the very last stage of atherosclerosis, 
have been also approximated. The activity of platelets has been visualized by targeting of 
glycoprotein IIb/IIIa (LIBS) in atherosclerotic mice (von zur Muhlen, von Elverfeldt et al. 
2008; Quillard and Libby 2012).  
 Beyond proposed molecular markers and contrast agents used in animal models, 
which identify only advanced atherosclerotic plaques, vascular adhesion (VCAM-1) 
molecules serve as an excellent target due to the fact that they are expressed early within 
lesions in atherosclerosis. VCAM-1 molecules appear very early on activated endothelial 
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cells leading to adhesion of leukocytes (Nakashima, Raines et al. 1998; Braun, Pietsch et 
al. 1999; Ley and Huo 2001). The chronic inflammatory process of atherosclerosis with 
the high level of cytokines and oxidized lipoproteins stimulates not only endothelial cells 
but also other plaque cells to enhanced expression of VCAM-1 (O'Brien, Allen et al. 1993; 
Huo and Ley 2001; Ley and Huo 2001; Libby 2002). Therefore they represent a valuable 
marker of early and advanced changes indicating ongoing inflammatory processes within 
diverse immune cells involved. In order to mark the VCAM-1 within the early and 
advanced atherosclerotic plaques, there must be a specific ligand which could recognize 
the adhesion molecules. Previous studies utilized antibodies as ligands to image VCAM-1 
molecules by ultrasound (Kaufmann, Sanders et al. 2007; Ferrante, Pickard et al. 2009) 
and by magnetic resonance (MR) imaging (Kelly, Nahrendorf et al. 2006; Nahrendorf, 
Jaffer et al. 2006; McAteer, Schneider et al. 2008). Other studies have focused on optical 
and nuclear modalities and have shown VCAM-1 expression by functionalized contrast 
agents linked with perfluorocarbon (Southworth, Kaneda et al. 2009), fluorine 
(Nahrendorf, Keliher et al. 2009), and radiolabeled technetium (Broisat, Hernot et al. 
2012). In the expanding molecular imaging field, use of small peptides offers a promising 
strategy for VCAM-1 targeting. The advantage of small peptides is their tiny size. As 
VCAM-1 ligand, they are mostly composed of only several amino acids and due to that the 
immunogenicity effect is diminished (Patel, Zaro et al. 2007; Delehanty, Boeneman et al. 
2010). Further they are inexpensive, easy to synthetize, biocompatible, and nontoxic for in 
vivo application. The use of small peptides ensures specific and controlled binding to only 
targeted cells expressing VCAM-1 (Patel, Zaro et al. 2007; Delehanty, Boeneman et al. 
2010). To guarantee this specific binding, the amino acid sequence within synthetized 
peptide needs to resemble the active amino acid binding sites presented in the α4β1 
complex expressed on leukocytes (presented in the chapter: 1.4. Role of α4β1as a co-
receptor of VCAM-1). Such a ligand binding site enables the interaction with the VCAM-
1. Thus small peptides linked with iron oxide nanoparticles can assure on the one site 
specific and controlled VCAM-1 binding and on the other site represent a compelling 
approach for MR visualization of the early and advanced atherosclerotic process. 
Additionally, internalization of targeted USPIO particles within atherosclerotic lesions 
occurs and might be initiated via receptor mediated endocytosis (Hillaireau and Couvreur 
2009). However the whole mechanism is still not known (Nair, Fukuda et al. 2012).  
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 In summary, USPIO iron oxide nanoparticles conjugated to specific VCAM-1 
peptide might offer not only a specific and sensitive MR detection of vascular adhesion 
molecules in the atherosclerotic plaques, but also permits the internalization of 
nanoparticles and their capture inside the targeted cells. Thus targeted iron oxide 
nanoparticles might be suitable for in vivo visualization of the cardiovascular system with 
atherosclerotic inflamed vessels and disturbed blood flow.   
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1.7. Aims of the thesis 
 
The aim of this thesis was to test the capability of newly developed USPIO particles with 
gem-bisphosphonate coating and conjugated to specific cyclic VCAM-1 peptide (Patent 
WO2004/058275, US 2004/253181, Guerbet Research France) to visualize early and 
advanced atherosclerotic plaques in apolipoprotein E deficient (ApoE-/-) mouse model 
using the unprecedented combination of ultra-high field MRI, together with the assessment 
of particle localization by histology and electron microscopy. The thesis involved ex vivo 
and in vivo experiments and was divided into four parts.  
 In the first part of this work atherosclerotic ApoE-/- mice were investigated in order to 
assess the formation of early and advanced plaques and the contribution of vascular cell 
adhesion (VCAM-1) molecules in the atherosclerotic inflammatory process. These 
experiments were conducted ex vivo and histological staining was performed to visualize 
the VCAM-1 expression within diverse immune cells involved in the pathophysiological 
development of atherosclerotic plaques.  
 The second part of this study examined the feasibility of newly synthesized 
ultrasmall superparamagnetic iron oxide (USPIO) particles conjugated with (P03011) or 
without (P3007) VCAM-1 binding peptide. The structure and stability of USPIO-VCAM-1 
and USPIO particles were analyzed by electron microscopy. The superparamagnetic 
characteristics of iron oxide particles in ex vivo phantoms were demonstrated by ultra-high 
magnetic field. Particle pharmacokinetics and biodistribution studies were performed by 
inductively coupled plasma emission spectroscopy and histology.  
 Third part involved in vivo application and validation of USPIO-VCAM-1 and 
control USPIO particles in C57Bl/6 control and atherosclerotic ApoE -/- mice at different 
time points in order to monitor VCAM-1 expression and inflammatory process within the 
12 and 30 week old atherosclerotic mice. In vivo detection of applied USPIO-VCAM-1 and 
control USPIO particles was conducted at ultra-high magnetic field. 
 The last part of this study examined cellular distribution of USPIO-VCAM-1 and 
control USPIO particles by histological assessment and electron microscopy.  
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2. Materials 
2.1. Chemicals 
 
Most of the chemicals used for preparation of histological staining and ex vivo MR 
experiments were supplied from Sigma-Aldrich. The list of chemicals and antibodies 
supplied from other companies are described in the Magnetic Resonance Imaging and 
Histology method section. 
 
2.2. Equipment 
 
Analytical Balance (max 120g)  KERN  
Analytical Balance (max 2000g) 440-47  KERN  
AVANCE 750 MHz Spectrometer  BRUKER BIOSPIN 
Channel Selector   BRUKER BIOSPIN 
Centrifuge 5415C   EPPENDORF 
Cooling Units UWK 45   HAAKE  
Cryotom CM1850   LEICA  
Fume Adsorber TAZ19   MEDITE 
Hood    KOETTERMANN 
Emission Spectrometer JY70 Plus  HORIBA JOBIN YVON  
Isoflurane Pump   EICKEMEYER  
Light microscope Axioskop 2 plus  ZEISS  
Fluorescent microscope Axiovision  ZEISS  
MS2 Minishaker   IKA 
NMR Network Analyzer   AEA TECHNOLOGY  
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Scantainer   SCANBUR  
RCT basic    IKA  
 
2.3. Contrast agents 
 
Non-targeted and targeted ultrasmall superparamagnetic iron oxide nanoparticles were 
obtained from Guerbet Research Laboratory (France). The synthesis of these particles is 
explained in patent number WO2004/058 275 (US 2004/253181) Guerbet Research 
Laboratory (France).  
 
2.3.1. P3007 (USPIO) 
 
Control non-targeted USPIO nanoparticles described in the patent number WO2004/058 
275 (US 2004/253181) consist of 5 nm iron oxide core with a layer of more gem-
bisphosphonate compounds (CH(PO3H2)2)n. These compounds are equipped with the -L2- 
linkage via which the amino PEG (polyethyleneglycol 750) group is attached to the 
compound (Patent WO2004/058 275, US 2004/253181 Guerbet Research France), 
(Michalska, Machtoub et al. 2012).       
 
2.3.2. P03011 (USPIO-VCAM-1) 
 
The targeted P03011 contrast agent was synthesized using USPIO iron oxide nanoparticles 
combined with a VCAM-1 specific peptide. The USPIO particles with 5 nm iron core 
possess a gem-bisphosphonate (CH(PO3H2)2)n coating which covers the particles. The 
particles’ covering layer of gem-bisphosphonate compounds is conjugated further to the 
specific cyclic VCAM-1 peptide via a carboxylate (RCOO-) group. This group enables 
stable coupling of the VCAM-1 peptide. Beside VCAM-peptide linkage, there are also 
amino PEG (polyethyleneglycol 750) groups coupled to the layer. The final size of USPIO-
VCAM-1 particles is 26 nm. The dissociation constant (Kd) value of the targeted particles 
is 61 nM. The sequence of the VCAM-1 peptide within the designed contrast agent was 
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tested within the cloning procedure (4 series of cloning) and the chosen cyclic sequence, 
composed of amino acids such as Cys-Asn-Asn-Ser-Lys-Ser-His-Thr-Cys (C-NNSKSHT-
C), signified the presence of asparagine, serine, lysine, histidine, and threonine within the 
peptide. The particular amino acids in the peptide demonstrated similarity of α4β1 integrin 
active sites and further demonstrated high significance for VCAM-1 recognition 
(Kd=1.03x10
-5M) (validation of the cyclic peptide sequence presented in Patent number 
WO2004/058 275, US 2004/253181, Guerbet Research France).  
 
2.3.3. Structure of P3007 and P03011 
 
The iron quantities within the nanoparticles were characterized by atomic absorption 
spectroscopy (Varian AA10 spectrophotometer). First the sample was mineralized by 40% 
hydrochloric acid (HCl) and diluted according to a standard series of ferric ions (0, 5, 10, 
15 and 20 ppm). The size of contrast agent was determined by Photon Correlation 
Spectroscopy (Malvern 4700) (Patent WO2004/058 275, US 2004/253181 Guerbet 
Research France) (Michalska, Machtoub et al. 2012). 
 
2.4. Experimental fodder 
2.4.1. Normal chow diet, SSNIFF Experimental Fodder Rat/Mouse  
 
This fodder is based on highly purified or semisynthetic components required for the 
animal diet which maintenance the growth and normal metabolism of the animals. The diet 
composes of 61 % of sugar, 30 % of proteins, 9 % of fat, minerals, and vitamins.  
 
2.4.2. Western diet, SSNIFF Experimental Fodder Rat/Mouse (TD88137) 
 
This diet contains high level of fat and cholesterol (40 %). The cholesterol content (2.071 
mg/kg) is adapted to the experimental animal approach to induce specific diseases such as 
atherosclerosis, obesity, or diabetes type 2. Apart from high content of lipids, this diet is 
enriched in 40 % of sugar, and 20 % of proteins, minerals, and vitamins.   
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2.5. Animal model 
 
The animal investigations were affirmed by local authorities (Regierung von Unterfranken, 
Würzburg, Germany) according to the German protection law of experimental animals. 
Prior to experiments, the animals were kept in Scantainer (Scanbur, Denmark) with the 
adjusted temperature of 24o C degree and humidity of 84%.  
 
2.5.1. C57Bl/6 mouse model  
 
C57Bl/6 mice, obtained from Charles River Laboratories Sulzfeld, Germany (strain code 
027), were used as a control background experimental animal model. C57Bl/6 is a standard 
inbred strain utilized for genetic modifications to study the human diseases for example as 
atherosclerosis (Knowles and Maeda 2000). In this study, control C57Bl/6 mice aged 4 
weeks were placed on normal diet and examined at 12 and 30 weeks.    
 
2.5.2. Apolipoprotein E deficient (ApoE-/-) mouse model 
 
 ApoE -/- mice, obtained from Charles River Laboratories Sulzfeld, Germany (strain code 
002052), served as an atherosclerotic animal model for all experimental measurements. 
ApoE-/- deficient mouse model was developed by genetic modification of C57Bl/6 control 
mice. These ApoE-/- mice possess elevated cholesterol level due to the lack of ApoE gene 
and hence are prone to develop atherosclerotic plaques. The plaque formation in ApoE-/- 
mice resembles human atherosclerotic lesions and due to that phenomenon this animal 
model is common for studying the pathophysiology of atherosclerosis (Hartley, Reddy et 
al. 2000; Meir and Leitersdorf 2004; Pendse, Arbones-Mainar et al. 2009). In this work, 
ApoE-/- animals aged 4 weeks were kept on a high fat diet for 8 weeks to study the early 
formation of the plaques and for 26 weeks to study the progression of the advanced 
plaques.   
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3. Methods 
3.1. Magnetic Resonance Imaging (MRI)  
3.1.1. Ultra-high field MR System 
 
All ex vivo and in vivo studies were conducted on an AVANCE 750 MHz Spectrometer 
from Bruker Biospin GmbH (Rheinstetten, Germany). The MR system consists of a 
vertical 17.6 Tesla ultra-high field superconducting magnet. This magnetic field is created 
by an electric current in the coils composed of superconducting wires. The advantage of 
these superconducting elements is that they can sustain very high electric currents without 
losses. The superconductivity is enabled by cooling the coils inside the MR system by 
liquid helium (Schroder and Faber 2011). Furthermore, the system is equipped with 
integrated shim coils to keep the magnetic field homogeneous. The inside diameter of the 
system is 89 mm. The MR system further comprises a 57 mm gradient system with a 
strength of 0.2 T/m and a 40 mm gradient system with a strength of 1 T/m. Both of the 
gradient units are actively shielded. The system also possesses an external gradient cooling 
unit (HAAKE) to regulate and adjust the temperature to all designed experiments. 
 
3.1.2. Tuning and matching of the radio-frequency (RF) coils 
 
During the tuning and matching procedure of a coil, the coils resonance frequency is tuned 
to the Larmor frequency (750 MHz) and its impedance is matched to that of the system (50 
Ohm). This procedure is performed by connecting the proton channel of the RF coil to the 
NMR Network Analyzer (AEA TECHNOLOGY). Good tuning and matching of the RF 
coils to 750 MHz frequency and to 50 Ohm enables good and high signal to noise ratio 
(SNR). Afterwards, the coil is connected to the spectrometer.  
 
3.1.3. Shimming 
 
The AVANCE 750 MHz spectrometer possesses an integrated system of coils for 
shimming in order to maintain a homogenous magnetic field. Shimming is performed by 
superimposing additional fields to the main field distorted by the sample before the MR 
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scan to avoid magnetic field inhomogeneities (Schroder and Faber 2011). MR imaging 
begins after completion of the shimming procedure. 
 
3.1.4. Sequences used for MR scans 
 
There are individual sequences developed in the Experimental Physics by Dr. Volker 
Herold (Herold, Wellen et al. 2009; Herold 2010) used for MR imaging and each of the 
sequences will be described separately in the ex vivo and in vivo MRI measurements 
section.     
 
3.2. MR Software  
3.2.1. ParaVision 4 
 
MR images were acquired using software ParaVision version 4 from Bruker Biospin 
GmbH (Rheinstetten, Germany). The software is designed for the routine MR 
measurements and manages the protocols and the sequences which are used for the 
experiments. The data acquired during the MR scan was transferred further as a DICOM 
file or the original data, and reconstructed in Matlab. 
 
3.2.2. Matrix Laboratory (Matlab) 
 
Acquired MR images were reconstructed in Matlab which is a commercial software 
provided by MathWorks (Natick, MA, USA). This is a program for data imaging. This 
software performs data reconstruction, programming, and diverse graphical presentations 
of the MR data.   
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3.3. Ex vivo and in vivo measurements at 17.6 T ultra-high field MR 
System   
 
Ex vivo and in vivo MR imaging was conducted on a 17.6 T vertical bore MR system 
(Bruker Biospin GmbH, Rheinstetten, Germany), using a 40 mm gradient system with a 
strength of 1 T/m. For ex vivo measurements a 5 mm 1H scroll coil and for in vivo 
measurements a 25 mm 1H birdcage coil was used (Tropp 1989; Lanz, Ruff et al. 2001; 
Lykowsky 2010). 
 
3.4. Ex vivo MRI measurements 
 
Validation of the contrast agent dose and calculation of relaxivity (r2) values of iron oxide 
contrast agents was executed via ex vivo MRI experiments. 
 
3.4.1. MR measurement of the contrast agent dose 
3.4.1.1. Preparation of the agar phantoms 
 
Reagents: 
4 % Formaldehyde   Sigma-Aldrich  
1.5 % Agarose   AppliChem  
 Agarose         
 Distilled water 
P3007 (USPIO)   Guerbet Research Laboratory 
P03011 (USPIO-VCAM-1)   Guerbet Research Laboratory 
Protocol: Validation of the contrast agent dose was performed in control C57Bl/6 and 
ApoE-/- mice injected with the P03011 (USPIO-VCAM-1) contrast agent ranging from 100 
µmol up to 600 µmol iron oxide/kg body weight. Hearts and aortae were isolated after 1 
hour, 6 hours and 24 hours. The same procedure was performed with the control P3007 
(USPIO) contrast agent. First of all C57Bl/6 and ApoE-/- mice were injected with 100, 300 
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and 600 µmol iron oxide / kg body weight and after 1 hour, 6 hours, and 24 hours hearts 
and aortae were excised. Hearts and aortae were further placed in 4 % formaldehyde for 1 
up to 12 hours. After fixation, the hearts and aortae were placed in 5 mm NMR tube and 
cast in 1.5 % agarose.  
 
3.4.1.2. 5 mm 1H scroll coil 
 
The 10 mm wide and 44 mm long scroll coil with inner diameter of 5 mm was used for ex 
vivo measurements. The coil is characterized by its excellent homogeneity and good signal 
to noise (SNR) and consists of a copper strip and a dielectric Teflon medium, which are 
rolled up together over a polyoxymethylene cylinder. This ensures that the capacity of the 
scroll coil cannot change by thermal expansion during the measurement (Grant, Sit et al. 
2007) (Lykowsky 2010).  
 
3.4.1.3. Sequence 
 
Fast Low-Angle Shot (FLASH) scout sequence 
Coronal, sagittal, and axial FLASH scout scans were utilized to image and orientate the 
measured object and served as a reference for setting the geometry of the further 
measurements. The parameters of the FLASH sequence were following: TR/TE= 60/2.9 
milliseconds, with an image resolution of 219 μm2 with a (28 x 28) mm2 coronal, sagittal, 
and axial field of view, BW = 79 kHz, NA = 1, number of echo images = 1, slice thickness 
= 1 millimeter, excitation pulse = hermite. The duration time of the image acquisition is 30 
seconds.       
 
T2-weighted 3D Multi Spin Echo (MSME) sequence 
An MSME sequence was used to obtain T2 values. The parameters of the 3D Multi Spin 
Echo (MSME) sequence were as follow: TR/TE = 1500/4.5 milliseconds, with an isotropic 
image resolution of 78 μm3 with a (5 x 5 x 20) mm3 transverse field-of-view, BW = 75 
kHz, NA = 2, number of echo images 40, excitation and refocusing pulse = hermite. The 
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experiment duration is 13 hours. Phantom data were reconstructed in Matlab (The 
MathWorks Inc, Natick, MA, USA) and zerofilled inplane from a 64 x 64 to a 128 x 128 
matrix. The quantification of the signal decay was calculated by fitting the T2 values pre- 
and post-contrast via a non linear least square fit to the function s(t) = exp(-t/T2). 
 
3.4.2. MR measurement of relaxation rate (r2) 
 
Protocol: Relaxivity (r2) values of iron oxide contrast agent were measured using a 2D 
MSME sequence (described above) and calculated in Matlab following the equation:  
1/T2Fe = (1/T2O) + λ[Fe] x ΔCFe 
r2Fe = 1/T2Fe  
r2O = 1/T2O 
ΔrFe-O = r2Fe – r2O 
λ[Fe] = ΔrFe-O/ΔCFe 
where T2Fe is the relaxation time of the sample containing iron oxide particles, T2O is the 
relaxation time of the pure buffer in which iron oxide is diluted, in this case NaCl. The 
following dilutions of iron oxide particles were prepared: 0.05 mmol, 0.1 mmol, 0.5 mmol, 
and 1 mmol. ΔrFe-O is the relaxation rate of the iron oxide particles, and ΔCFe is the 
concentration of iron oxide. λ[Fe] is the relaxivity of the iron oxide particles measured 
[mmol-1 s-1]. 
 
3.5. In vivo MRI measurements  
 
In vivo measurements were conducted on 12 and 30 week old C57Bl/6 and ApoE-/- mice 
before and 1 hour, 6, and 24 hours after injection of P03011 (USPIO-VCAM-1) and P3007 
(USPIO) contrast agent.  
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3.5.1. Preparation of the mouse for the measurement 
 
Reagents: 
Isoflurane   Abbott  
P3007 (USPIO)   Guerbet Research Laboratory 
P03011 (USPIO-VCAM-1)   Guerbet Research Laboratory 
Protocol: C57Bl/6 and ApoE-/- mice were anaesthetized by placing them into the specially 
designed box filled with 4 % isoflurane and 0.2 L/minute oxygen for 3 to 5 minutes under 
the hood (Koettermann). The mice were transferred afterwards and prepared for the 
measurement on the table equipped with 1-1.5 % isoflurane pipe and a fume adsorber 
(TAZ 19 Medite). The regulation of the isoflurane and oxygen level was controlled via 
isoflurane pump (Eickemeyer). During this time the linear birdcage 25 mm coil, used for in 
vivo study, was prepared. The coil was firstly placed under the red light and warmed up. 
The procedure of warming the coil helped to sustain physiological temperature of the 
mouse body. Further the mice were positioned inside the coil exactly within the center of 
the coil to guarantee the best signal to noise ratio (SNR) of the heart region. To control the 
ECG signal, an ECG balloon was placed in the center of the coil, within the chest where 
the apex of the mouse heart is, to control the triggering of the heart. The ECG balloon was 
further connected to the ECG trigger Unit HR from Rapid Biomedical. This device enabled 
exact monitoring of the health state of the mouse, allowing adjustment of the anaesthesia 
level. Moreover, the ECG signal was used as trigger for the MR measurements to rule out 
artifacts caused by the motion.      
 
3.5.2. Linear 25 mm 1H birdcage coil 
 
In vivo studies were performed with a custom built linear birdcage coil with 25 mm 
diameter and 35 mm inner leg length. The increased diameter compared to standard coils 
facilitated in vivo measurements of mice with a body weight of 20 to 30 g in the 40 mm 
gradient insert. The 25 mm inner diameter tube served as a rail for the animal fixation and 
provided with the easy access of the desired heart location. The advantage of linear 
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birdcage coil use for in vivo animal studies is the high sensitivity, and homogeneity 
through the transversal plane (Hayes 1985; Lykowsky 2010; Schroder and Faber 2011). 
 
3.5.3. Sequence 
 
All sequences used for in vivo MRI were ECG triggered.  
 
Scout longitudinal Fast Low-Angle Shot (FLASH) sequence 
Longitudinal FLASH scout movies (CINE FLASH) were acquired and used to image and 
orientate the mouse heart. During the CINE FLASH scans the ECG signal of the cardiac  
cycle was triggered to acquire the MR data allowing the phase and readout encoding steps 
and further data reconstruction (Figure 3.1).  
    
Figure 3.1. CINE FLASH MR images of the mouse heart. ECG signal of the heart rate is triggered 
and the acquired data is encoded in the k-space allowing further reconstruction of the frame images of 
the heart cycle.  
The parameters of the FLASH scout were as follow: TR/TE = 7/1.5 milliseconds, with an 
isotropic image resolution of 117 μm2 with a (30 x 30) mm2 sagittal field-of-view, BW = 
75 kHz, NA = 1, number of echo images 1, excitation pulse = gauss, number of slices = 1, 
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slice thickness = 0.8 mm, number of movie frames = 8. Duration time of scan is 30 
seconds. Within the CINE FLASH image two transverse slices were positioned in order to 
perform the second scan using the Transversal FLASH sequence (Figure 3.2). 
      
Figure 3.2. Scout longitudinal Fast-Low Angle Shot (FLASH) image of the mouse trunk with two 
transversal slices positioned within the heart (the upper slice) and within the liver (the lower slice) 
used for the acquisition of ascending and descending aorta. 
 
Transversal Fast Low-Angle Shot (FLASH) sequence  
Transversal FLASH movies were acquired to visualize ascending and descending aorta. 
This scan used the geometry from the scout longitudinal FLASH image (Figure 3.2 and 
Figure 3.3 A) with one slice positioned within the ascending aorta in the heart (Figure 3.3 
B)  and one slice positioned within the descending aorta within the lower part of the mouse 
body (Figure 3.3 C). The parameters of the FLASH sequence were: TR/TE = 14/1.8 
milliseconds, with a non-isotropic image resolution of 117 x 234 μm2 with a (30 x 30) mm2 
transversal field-of-view, BW = 75 kHz, NA = 1, number of echo images 1, excitation 
pulse = gauss, number of slices = 2, slice thickness = 1 mm, number of movie frames = 8. 
Duration time of the measurement is 30 seconds. 
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Figure 3.3. Longitudinal Fast Low-Angle Shot (FLASH) image of the mouse trunk  with the slice 
selection (A). Transversal image of the ascending (B) and descending (C) aorta. The selected slices 
within the longitudinal (A) and transversal (B, C) images assured proper acquisition of the entire 
mouse aorta. 
 
Longitudinal Fast Low-Angle Shot (FLASH) sequence 
The last longitudinal FLASH movie was acquired to image diastolic and systolic moment 
of the heart (Figure 3.4). This scan used the geometry from the previous transversal 
FLASH image (Figure 3.3). The FLASH sequence used the following details: TR/TE = 
12/1.8 milliseconds, with an isotropic image resolution of 117 μm2 with a (30 x 30) mm2 
sagittal field-of-view, BW = 75 kHz, NA = 1, number of echo images 1, excitation pulse = 
gauss, number of slices = 1, slice thickness = 1.4 mm, number of movie frames = 8. 
Duration time is 30 seconds. 
       
Figure 3.4. Longitudinal Fast Low-Angle Shot (FLASH) image of the ascending and descending 
aorta. 
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T2*-weighted Fast Low-Angle Shot (FLASH) sequence 
A T2*-weighted FLASH sequence in axial slice-orientation was used to image the aortic 
root region (Figure 3.5 B). The iron oxide contrast agent distribution was visualized using 
the bright blood method of the FLASH sequence: TR/TE = 3/1 milliseconds, with an 
isotropic image resolution of 98 μm2 with a 30 x 30 mm2 transverse field-of-view and a 
slice thickness of 0.5 mm, BW = 200 kHz, NA = 8, number of echo images 1, excitation 
pulse = gauss, number of slices = 1, slice thickness = 0.5 mm, duration time = 8 minutes. 
    
Figure 3.5. Longitudinal FLASH image (A) with the selected slice for the T2*-weighted image 
acquisition (B). 
 
3.5.4. Data Analysis 
 
The feasibility of P03011 (USPIO-VCAM-1) and P3007 (USPIO) contrast agent was 
scrutinized by investigating the signal loss within the aortic root from control C57Bl/6 and 
ApoE-/- mice before and after contrast agent administration. T2*-weighted in vivo MR 
images were analyzed for signal to noise ratio (SNR) and contrast to noise ratio (CNR) 
variations of the signal intensity loss caused by iron oxide nanoparticles. Mean signal 
intensity (SI) was calculated by drawing a region of interest (ROI) within the aortic lumen 
to assess the mean blood signal (SI blood) and within the aortic plaque area of the root for 
the mean plaque signal (SI aortic wall) estimation (Figure 3.6). Due to the time interval 
between the MR measurements and changing the position of the mouse inside the coil, the 
parameters such as standard deviation (SD) of the mean background signal and mean blood 
signal intensity, were measured and utilized as a reference for contrast to noise ratio (CNR) 
correction (Michalska, Machtoub et al. 2012).  
44 
 
SNR values were calculated using the formula (Kuo and Herlihy 2008; Schroder and 
Faber 2011): 
SNR pre = SI aortic wall pre / SD noise pre 
SNR post = SI aortic wall post / SD noise post 
CNR values were estimated using the following calculations (Kuo and Herlihy 2008; Klug, 
Kampf et al. 2009): 
CNR pre = (SI blood pre – SI aortic wall pre) / SD noise pre  
CNR post = (SI blood post – SI aortic wall post) / SD noise post  
The statistical representation of SNR and CNR was demonstrated by 1-way ANOVA test 
(GraftPad Prism Software). Data were statistically relevant in case of P<0.05. 
 
Figure 3.6. T2*-weighted image of aortic root region of atherosclerotic ApoE
-/-
 mouse (A, B) 
prior to and (C) post contrast agent application. (B, C) Region of interest (ROI), pre and post iron 
contrast agent injection was drawn within the aortic lumen to assess the mean blood signal (SI blood) 
and within the aortic plaque area of the root for the mean plaque signal (SI aortic wall) estimation. 
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3.6. Histological staining 
3.6.1. Tissue preparation 
 
After in vivo MRI experiments, the control C57Bl/6 and ApoE-/- animals were prepared for 
further histological examination. After cervical dislocation of the mouse neck, the heart 
with ascending aorta and other organs including brain, lungs, liver, kidneys, spleen, para-
aortic lymph nodes, and skeletal muscle were excised and rinsed with 2 ml of NaCl. All 
tissue organs were next washed 3 minutes with Phosphate Buffered Saline (PBS), and 5 
minutes cooled in isopentane (-20° C) followed by freezing in liquid nitrogen. Organs were 
then fixed in Tissue-Tek (Sakura, Netherlands) at -24o C degrees in the cryotome and 
cryosliced at 8 μm for (immune) histology, Haematoxylin & Eosin Staining, Oil Red O 
Staining, and at 25 μm for Prussian Blue Staining. Prepared tissue sections were kept at 
room temperature overnight to allow drying of the sliced sections.  Dried sections were 
then transferred into the cooling boxes and kept in -20o C degrees until the beginning of the 
staining procedure.   
 
3.6.2. Immune-Histological staining 
3.6.2.1. CD 68 VCAM-1 double staining 
 
Principle: The distribution of adhesion molecules VCAM-1 (CD106), macrophages 
(CD68) and their co-localization within the aortic wall of the atherosclerotic mice was 
demonstrated by immunofluorescent method using specific antibodies linked to the 
fluorescent dye (immune-double staining).  
Reagents:  
PBS (Dulbecco, L182-50)   Biochrom  
3 % Blocking Goat Serum (S-1000)  Vector Laboratories  
10 µg/mL Streptavidin-FITC  (SA-5001)  Vector Laboratories  
Avidin/Biotin Blocking (SP-2001)  Vector Laboratories 
10 µg/mL Streptavidin Alexa Fluor 546 (S11225) Invitrogen  
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1µg/mL DAPI Staining (268298)  Merck 
Vectashield Mounting Medium  Vector Laboratories 
 
Antibody targeting Macrophages (CD68): 
- 1o primary antibody CD68  (MCA 1957)  AbD Serotec 
Rat anti mouse (0.25 mg/mL, 1:75 diluted in 3% goat serum) 
- secondary biotinylated antibody (BA-9400) Vector Laboratories  
Goat anti rat (1:300 diluted in 3% goat serum) 
 
Antibody targeting VCAM-1 (CD106): 
- 2o primary VCAM-1 biotinylated  Linaris  
(0.1 mg/mL, 1:50 diluted in 3% goat serum) 
Protocol: After tissue fixation for 5 minutes in ice-cold acetone the prepared 8 µm slides 
were stained utilizing the following procedure: the dried slides were washed 3 times in 
PBS, and blocked with 3 % blocking goat serum for 20 minutes. After the blocking step, 
the slides were incubated with the first primary antibody (CD 68) for 90 minutes, washed 3 
times with PBS, and then the secondary biotinylated antibody was added for 30 minutes. 
Further, the slides were incubated with Streptavidin-FITC mixture for 30 minutes and 
washed in PBS for 5 minutes. Sections were then blocked by Avidin/Biotin Blocking 
solution for 15 minutes, and washed in PBS for 5 minutes. Then the second primary 
VCAM-1 biotinylated antibody was incubated overnight at 4o C. Secondary detection for 
VCAM-1 was performed using streptavidin-Alexa Fluor 546 solution. Sections were 
washed in PBS for 5 minutes and counterstained with DAPI for visualization of nuclei, 
then coverslipped using Vectashield anti-fade mounting medium. Images were taken using 
a Zeiss Axiovision fluorescent microscope (Carl Zeiss MicroImaging GmbH, Germany). 
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3.6.2.2. vWF VCAM-1 double staining 
 
Principle: The distribution of adhesion molecules VCAM-1 (CD106) and endothelial cells 
(vWF) and their co-localization within the aortic wall of the atherosclerotic mice was 
demonstrated by immune-double staining.  
Reagents:  
PBS (Dulbecco, L182-50)   Biochrom  
3 % Blocking Rabbit Serum  (S-5000)  Vector Laboratories 
10 µg/mL Streptavidin-FITC  (SA-5001)  Vector Laboratories 
Avidin/Biotin Blocking Kit (SP-2001)  Vector  
10 µg/mL Streptavidin Alexa Fluor 546 (S11225) Invitrogen 
1µg/mL DAPI Staining (268298)  Merck 
Vectashield Mounting Medium (H-1000)  Vector Laboratories  
 
Antibody targeting Endothelial cells (vWF): 
- 1o primary antibody vWF (ab11713)  Abcam 
Sheep anti mouse (1:100 diluted in 3 % rabbit serum) 
- secondary biotinylated antibody (BA-6000 ) Vector Laboratories  
Rabbit anti sheep (1:300 diluted in 3% rabbit serum) 
 
Antibody targeting VCAM-1 (CD106): 
- 2o primary VCAM-1 biotinylated  Linaris  
(0.1 mg/ml, 1:50 diluted in 3 % rabbit serum) 
Protocol: After tissue fixation for 5 minutes in ice-cold acetone the prepared 8 µm slides 
were stained utilizing the following procedure: the dried slides were washed 3 times in 
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PBS, and blocked with 3 % blocking rabbit serum for 20 minutes. After the blocking step, 
the slides were incubated with the first primary antibody (vWF) for 90 minutes, washed 3 
times with PBS, and then the secondary biotinylated antibody was added for 30 minutes. 
Further, the slides were incubated with Streptavidin-FITC mixture for 30 minutes and 
washed in PBS for 5 minutes. Sections were then blocked by Avidin/Biotin Blocking 
solution for 15 minutes, and washed in PBS for 5 minutes. Then the second primary 
VCAM-1 biotinylated antibody was incubated overnight at 4o C. Secondary detection for 
VCAM-1 was performed using streptavidin-Alexa Fluor 546 solution. Sections were 
washed in PBS for 5 minutes and counterstained with DAPI for visualization of nuclei, 
then coverslipped using Vectashield anti-fade mounting medium. Images were taken using 
a Zeiss Axiovision fluorescent microscope (Carl Zeiss MicroImaging GmbH, Germany). 
 
3.6.2.3. α smooth muscle actin VCAM-1 double staining 
 
Principle: The distribution of adhesion molecules (VCAM-1) and smooth muscle cells (α 
smooth muscle actin, α SMA) and their co-localization within the aortic wall of the 
atherosclerotic mice was demonstrated by immune-double staining. 
Reagents:  
PBS (Dulbecco, L182-50)   Biochrom 
3 % Blocking Goat Serum (S-1000)  Vector Laboratories  
10 µg/mL Streptavidin-FITC (SA-5001)  Vector Laboratories  
Avidin/Biotin Blocking Kit (SP-2001)  Vector Laboratories  
10 µg/mL Streptavidin Alexa Fluor 546 (S11225) Invitrogen 
1µg/mL DAPI Staining (268298)  Merck 
Vectashield Mounting Medium (H-1000)  Vector Laboratories  
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Antibody targeting smooth muscle cells (α smooth muscle actin, α SMA): 
- 1o primary antibody α SMA (ab7817)  Abcam 
Rabbit anti mouse (1:100 diluted in 3 % goat serum) 
- secondary biotinylated antibody (BA-1000 )  Vector Laboratories  
Goat anti rabbit (1:300 diluted in 3 % goat serum) 
 
Antibody targeting VCAM-1 (CD106): 
- 2o primary VCAM-1 biotinylated  Linaris  
(0.1 mg/ml, 1:50 diluted in 3 % goat serum) 
 
Protocol: After tissue fixation for 5 minutes in ice-cold acetone the prepared 8 µm slides 
were stained utilizing the following procedure: the dried slides were washed 3 times in 
PBS, and blocked with 3 % blocking goat serum for 20 minutes. After the blocking step, 
the slides were incubated with the first primary antibody (α SMA) for 90 minutes, washed 
3 times with PBS, and then the secondary biotinylated antibody was added for 30 minutes. 
Further, the slides were incubated with Streptavidin-FITC mixture for 30 minutes and 
washed in PBS for 5 minutes. Sections were then blocked by Avidin/Biotin Blocking 
solution for 15 minutes, and washed in PBS for 5 minutes. Then the second primary 
VCAM-1 biotinylated antibody was incubated overnight at 4oC. Secondary detection for 
VCAM-1 was performed using streptavidin-Alexa Fluor 546 solution. Sections were 
washed in PBS for 5 minutes and counterstained with DAPI for visualization of nuclei, 
then coverslipped using Vectashield anti-fade mounting medium. Images were taken using 
a Zeiss Axiovision fluorescent microscope (Carl Zeiss MicroImaging GmbH, Germany). 
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3.6.3. Staining of the tissue / cell structure 
3.6.3.1. Haematoxylin Eosin (H&E) Staining 
 
Principle: Morphology, structure, and the composition of the diverse cells within the aortic 
wall of the control and atherosclerotic mice were shown by Haematoxylin Eosin (H&E) 
Staining according to the Lillie Mayer’s method (Fischer, Jacobson et al. 2008). 
Reagents:  
Haematoxylin    
 3g Haematoxylin (3816.2)  Roth  
 0.5g Natriumjodat (6525)  Merck 
 125g Aluminiumkaliumsulfate (1.01042) Merck  
 125g Chloralhydrate (1.02425)  Merck  
 2.5g Citric Acid 
 add 2.5 ml distilled water 
Bluing Agent    
Eosin     
 1g Eosin (1.5935)   Merck  
 add 100 ml distilled water 
96% Ethanol    Sigma Aldrich 
Xylene (16446)    Sigma Aldrich  
Rotihistol (6640.2)   Roth  
Entellan, Mounting Medium (1.07960)  Merck  
Protocol: After 5 minutes washing in distilled water, all 8 µm slides were incubated with 
haematoxylin for 10 minutes, rinsed with distilled water for 10 minutes. The sections were 
then washed in distilled water and incubated with eosin for 5 minutes, dehydrated in 100 % 
ethanol, followed by Xylene and Rotihistol for 5 minutes each and cover slipped.  The 
H&E stained images were acquired with the magnification of x 10 and x 20 and analyzed 
with SPOT Basic software (SPOT Imaging Solutions-Diagnostic Instruments, Inc, USA). 
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3.6.3.2. Oil Red O Staining  
 
Principle: Lipids within the aortic wall of the atherosclerotic mice were detected by Oil 
Red O Staining. 
Reagents:  
0.5 g Oil Red O stock solution (00625)  Sigma-Aldrich 
100 ml Isopropanol (1.09634 )  Merck 
30 ml Oil Red working solution  
 20 ml Distilled water 
Glycerol-Gelatine   
 10 g Gelatin  
 60 ml Distilled Water  
 70 ml Glycerol  
 0.25 g Phenol  
Protocol: 8 µm sections of mouse aortas were fixed in 4 % formaldehyde and washed in 
distilled water for 10 minutes. After this step the slides were in 60% isopropanol and 
stained with fresh Oil Red O solution for 15 minutes. Again submerged in 60 % 
isopropanol for 5 minutes slides were counterstained in haematoxylin for 3 minutes for the 
nuclear stain. The slides were then rinsed with distilled water and imbedded in glycerol 
gelatine. The Oil Red O stained images were acquired with the magnification of x 20 and x 
40 and analyzed with SPOT Basic software (SPOT Imaging Solutions-Diagnostic 
Instruments, Inc, USA) (Kinkel, Fernyhough et al. 2004). 
 
3.6.3.3. Prussian Blue (PB) Staining  
 
Principle: Iron oxide particles within the aortic wall of the atherosclerotic mice were 
detected using the method described by Mallory.  
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Reagents:  
-20oC Aceton (32201)   Sigma-Aldrich  
-20oC Methanol (32213)   Sigma-Aldrich 
Potassium hexacyano-ferrate (1.04984)  Merck   
37% Hydrochloric Acid (1.00317)  Merck 
0.1% Nuclear-fast Red (1.15939)  Merck 
Working solution    
 5% Potassium Ferrocyanide  
 5% Hydrochloric Acid  
Entellan, Mounting Medium (1.07960)  Merck  
Protocol: The 25 µm sections of the mouse aortic wall were fixed in cold acetone and 
methanol (1:1) for 10 minutes. After drying slides were incubated in working solution for 
30 minutes, rinsed with distilled water, counterstained with nuclear fast red solution for 5 
minutes, washed, dehydrated in Ethanol and cover slipped. The images were taken with 
Zeiss light microscope (Axioskop 2 plus). The iron stained images were acquired with the 
magnification of x 20 and x 40 and analyzed with SPOT Basic software (SPOT Imaging 
Solutions-Diagnostic Instruments, Inc, USA) (Schroeter, Saleh et al. 2004). 
 
3.6.3.4. Picrosirius Red Staining 
 
Principle: The collagen within the aortic wall of the atherosclerotic mice was detected by 
picrosirius red staining (Junqueira, Bignolas et al. 1979).  
Reagents:  
Picric Acid (80450)   Fluka  
Sirius Red    
 0.1 % in picric acid 
 1L distilled water  
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96 %, 75 %, 50 % Ethanol   
Xylene-Rotihistol  
Protocol: The sections were stained in picrosirius red for 20 minutes, washed in distilled 
water for 2 times, dehydrated in 96 %, 75 %, and 50 % ethanol, followed by Xylene-
Rotihistol incubation and cover slipped. The images of each section were recorded under 
bright field with the magnification of x 20 and x 40 and analyzed with SPOT Basic 
software (SPOT Imaging Solutions-Diagnostic Instruments, Inc, USA).  
 
3.7. Pharmacokinetics (PK) 
3.7.1. Blood sample preparation 
 
Control C57Bl/6 and ApoE-/- mice were prepared for pharmacokinetics assessment of 
P03011 (USPIO-VCAM-1) and P3007 (USPIO) particles. The control and atherosclerotic 
mice were firstly anaesthetized with 2.5 % isoflurane 0.2 L/min oxygen and placed under 
the fume adsorber. 600 µmol/ kg body weight of P03011 (USPIO-VCAM-1) and P3007 
(USPIO) contrast agent was injected intravenously and the blood samples were taken from 
the eye via retro-orbital bleed after 30 minutes, 2 hours, 5 hours, and 24 hours and further 
collected into microtainer SST tubes (BD Becton, Dickinson Company, NJ, USA). The 
control blood samples from the mice without application of contrast agent were also 
collected. The samples were further centrifuged 2 minutes at 13000 g and serum was taken 
for ICP-ES analysis to estimate the iron content within the plasma at different time after 
the blood collection (Michalska, Machtoub et al. 2012).  
 
3.7.2. Inductively coupled plasma emission spectroscopy (ICP-ES) measurement 
 
200 µl of  the serum samples taken from the animals before and after 30 minutes, 2, 5, and 
24 hours after contrast agent application, were transferred into the special glass tubes made 
from quartz. The quartz tubes containing serum were then filled with 1 ml of 65 % HNO3 
and incubated for 10 hours at 160-170o C degree. Prior to the measurements the quartz 
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samples were diluted with ultrapure water. The iron content within the samples was 
determined as mg/L via ICP-ES (Horiba Jobin Yvon GmbH, France). 
 
3.7.3. Data Analysis 
 
The circulation time of nanoparticles was calculated by the following equation: N(t)=N0e
-bt 
and fitted via the nonlinear least square fit: T1/2=log(2)/b, dT1/2=(log(2)db)/b
2. N0 means 
the original amount of iron particles that declines within time, N(t) is the iron content that 
rests and has not yet disappeared after a time t, and T1/2 is the half-life time of the declining 
contrast agent, fitted value b is linked to half-life time (T1/2), the db is the error of the fitted 
value b, and dT1/2 is the error of the half-life time (Michalska, Machtoub et al. 2012). 
 
3.8. Electron Microscopy (EM) 
 
Principle: Beside histological examination of iron oxide nanoparticles within the aortic 
wall of the atherosclerotic mice, these particles were further examined and visualized 
utilizing electron microscopy device from Zeiss EM10. Electron microscopy method 
enables, more than histology, investigation of iron nanoparticles localization in the extra- 
and intracellular compartments. 
Reagents:     
2.5 % Glutaraldehyde   Sigma-Aldrich  
50 mM cacodylate pH 7.2    
 50 mM KCl,        
 2.5 mM MgCl2 
Cacodylate    Sigma-Aldrich  
Osmium tetroxide (OsO4)   Sigma-Aldrich  
0.5 % uranyl acetate   Sigma-Aldrich  
100 % Ethanol    Sigma-Aldrich  
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Protocol: Hearts containing the aortic root were fixed with 2.5 % glutaraldehyde for 12 
hours at 4° C. Embedded hearts were washed three times for 5 minutes with 50 mM 
cacodylate (pH 7.2) and then fixed 2 hours at 4°C with 2 % osmium tetroxide mixed with 
50 mM cacodylate (pH 7.2). Hearts were then washed with H2O and stored overnight at 
4°C with 0.5 % uranyl acetate (in H2O).  After incubation, the tissue of the embedded 
hearts was dehydrated in ethanol, fixed in Epon812 and ultrathin sectioned. Ultrathin 
sections were either analyzed directly or stained with 2 % uranyl acetate (in ethanol) 
followed by lead citrate. Nanoparticles were best visible on ultrathin sections that were not 
post stained. Sections were analyzed with a Zeiss EM10 and EM900 (Zeiss, Oberkochen, 
Germany). Negatives were digitalized by scanning and processed by Adobe Photoshop 
(Prufert, Vogel et al. 2004; Michalska, Machtoub et al. 2012).  
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4. Results 
4.1. Characterization of atherosclerotic plaques 
 
The experiments within the first part of this thesis were designed in order to investigate the 
involvement of diverse immune cells and the contribution of vascular cell adhesion 
(VCAM-1) molecules in the early lesions and advanced plaque progression. Aortic wall 
morphology of control C57Bl/6 and atherosclerotic ApoE-/- mice aged 12 and 30 weeks 
was presented by histological staining utilizing haematoxylin and eosin (H&E) stain 
method and Prussian Blue staining. Analysis of immune cell distribution and their co-
localization with VCAM-1 molecules within early and advanced atherosclerotic plaques 
was presented by double immunofluorescent staining. 
 
4.1.1. Early atherosclerotic plaques 
 
The observation of the aortic wall of young 12 week old ApoE-/- mice fed a high cholesterol 
diet for 8 weeks showed that these mice developed mild lesions which appeared within 
ascending aorta (data not shown, and Figure 4.1). The aortic root regions of these 12 
week old ApoE-/- mice revealed explicit changes (Figure 4.1) characterized by recruited 
leukocytes into subendothelium. The thickening process at the early stage was modest and 
occurred only to a lower extent at the atheroma-prone sites retaining the media region 
unaltered. In contrast to visible changes within ascending aorta from young 12 week old 
atherosclerotic ApoE-/- mice, control C57Bl/6 mice kept on a normal chow diet did not 
develop any lesions (Figure 4.1). The morphology of the control C57Bl/6 root region 
represented the normal intimal and medial areas of aortic wall.    
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Figure 4.1. Morphology of the aortic wall from control C57Bl/6 and 12 week old atherosclerotic 
ApoE
-/- 
mice (representative image of histological examinations from n=3 mice, magnification x5). 
The cellular distribution of endothelial cells, macrophages, and smooth muscle cells within 
aortic root region from young ApoE-/- mice was further analyzed by immunofluoresent 
method. The distribution of fat droplets (detected by Oil Red O Staining) and collagen 
deposition (detected by Picrosirus Staining) was also performed (Figure 4.2 and Figure 
4.3). The young 12 week old ApoE-/- mice exposed to high fat diet developed mild lesions 
which composed of newly recruited leukocytes mostly monocytes. The phagocytosis 
process of oxidized lipoproteins was also presented in the young atherosclerotic plaques 
within aortic root region (Figure 4.2 B). 
    
Figure 4.2. Distribution of the fat droplets demonstrated by red stained region on Oil Red O 
staining image (B) within the early plaques of aortic root region from 12 week old ApoE
-/-
 mice 
(A) (representative image from n=3 ApoE
-/-
 mice, magnification x5). 
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The fat droplets presented by Oil Red O staining were distributed within the intimal 
endothelial and smooth muscle cells as well as within the deeper region of the formed 
plaques where the recruited macrophages as foam cells were detected (Figure 4.2 B and 
Figure 4.3 C-E). The endothelial cells presented by von Willenbrand factor (vWF) 
immunofluorescent staining were localized throughout the intimal region of atherosclerotic 
wall (Figure 4.3 C). The content of newly recruited macrophages of young 12 week old 
ApoE-/- mice was demonstrated by CD68 immunofluorescent staining (Figure 4.3 D). The 
monocytes/macrophages appeared within the atheroma-prone sites and further localized as 
foam cells abundantly within the subendothelial region of formed early plaques. The 
smooth muscle cells migration into intimal region of the aortic root from 12 week old 
ApoE-/- mice was also observed (Figure 4.3 E). These immune staining pointed already the 
manifestation of inflammatory process within young plaques. Besides the large 
macrophage colony within the early lesions, these plaques were also characterized by the 
substantial collagen deposits within the regions where the intimal smooth muscle cells 
resided (Figure 4.3 F). The immunofluorescent staining of vascular cell adhesion 
molecules (Figure 4.3 B) showed that the VCAM-1 expression appeared in the intimal line 
where endothelial, smooth muscle cells resided and demonstrated their co-localization with 
VCAM-1 (Figure 4.3 B, C, E). Further in the deeper region of the plaque where the 
macrophages were present, the strong VCAM-1 expression emerged (Figure 4.3 B, D). 
The VCAM-1 upregulation was also highly detected within the medial smooth muscle cells 
in the elastic lamina regions (Figure 4.3 B, E). 
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Figure 4.3. Cellular distribution and VCAM-1 molecules (CD106) expression pattern within the 
aortic root region from 12 week old atherosclerotic ApoE
-/- 
mice. (A) Morphology of the aortic 
root from young 12 week old ApoE
-/-
 mice, (B) Immunofluorescent staining of VCAM-1 (CD106) 
within the intima and media, (C-E) Double immunofluorescent staining of VCAM-1 (red stain) within 
endothelium (vWF) (green stain), macrophages (CD68) (green stain), and smooth muscle cells (SM 
actin) (green stain). Yellow merge represents co-localization of VCAM-1 molecules with endothelium 
(vWF), macrophages (CD68), and smooth muscle cells (SMactin). (F) Collagen deposition within the 
intimal and medial region. Representative images of histological examinations from n=3 mice, 
magnification x5. 
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4.1.2. Advanced atherosclerotic plaques  
 
The experiments within this work revealed that ApoE-/- mice fed a high fat diet for 26 
weeks possessed mature plaques within ascending aorta affecting aortic root, aortic arch, 
and the bifurcation region. Besides the marked changes within ascending aorta, the 
enhanced and sophisticated inflammatory process affected also the descending aorta 
leading to lesions’ development within abdominal region (data not shown). The 
composition of the advanced plaques within ascending and descending aorta was similar 
and composed of foam cells which created the fibrous cap. These plaques were 
characterized further by the presence of necrotic cores beneath the fibrous cap. The 
morphology of the aortic wall within the aortic root of intimal and medial region was 
significantly altered. In contrast to the young ApoE-/- mice, the thickening process of aortic 
root region was homogenous and occurred throughout the whole aortic wall. Driven by the 
enhanced chronic inflammation, the advanced thickening process caused the narrowing of 
lumen and provoked further changes within the medial elastic lamina regions (Figure 4.4). 
   
Figure 4.4. Morphology of the aortic wall from control C57Bl/6 and 30 week old atherosclerotic 
ApoE
-/- 
mice (representative image of histological examinations from n=3 mice, magnification x5). 
The cellular distribution of diverse immune cells involved in the advanced plaque 
formation was demonstrated by double immunofluorescent staining. The fat and collagen 
deposition was indicated by Oil Red O and Picrosirus Staining (Figure 4.5 and Figure 
4.6). 30 week old ApoE-/- mice demonstrated fat droplets within the intimal region where 
endothelial and smooth muscle cells occurred and also deeper in the subendothelial fibrous 
cap region and necrotic core where foamy and apoptotic macrophages were localized 
(Figure 4.5 B and Figure 4.6 C-E).   
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Figure 4.5. Distribution of the fat droplets demonstrated by red stained region on Oil Red O 
staining image (B) within the advanced plaques of aortic root region from 30 week old ApoE
-/-
 
mice (A) (representative image from n=3, magnification x5). 
Within advanced plaques immune cells were broadly distributed and altered the plaque 
composition (Figure 4.6). These plaques were characterized by presence of foamy and 
fibrous lesions and differed from the early plaques (Figure 4.1 and Figure 4.4). 
Macrophages, presented by CD68 immunofluorescent staining, appeared as foamy cells 
within the fibrous region and to a lower extent within the region of necrotic core of 30 
week old ApoE-/- mice (Figure 4.6 D). The necrotic core of advanced plaques contained 
besides foamy macrophages also smooth muscle cells and was characterized by the 
presence of apoptotic cells. The smooth muscle cells, demonstrated by immunofluorescent 
staining of α-smooth muscle actin (SM actin), were found within intimal and deeper 
regions of the advanced lesions (Figure 4.6 E). Collagen deposits were abundantly 
detected within intima where smooth muscle cells were present and also deeper within the 
necrotic core region where medial smooth muscles emerged (Figure 4.6 F). The staining 
of vascular cell adhesion molecules (Figure 4.6 B) revealed enhanced VCAM-1 
expression within the endothelial as well as intimal smooth muscle cells (Figure 4.6 B, C, 
and E). Further VCAM-1 was detected in the deeper region of the fibrous plaque localized 
to foamy macrophages (Figure 4.6 D) and also within the medial smooth muscle cells 
(Figure 4.6 E).   
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Figure 4.6. Cellular distribution and VCAM-1 molecules (CD106) expression pattern within the 
aortic root region from 30 week old atherosclerotic ApoE
-/- 
mice. (A) Morphology of the aortic 
root from 30 week old ApoE
-/- 
mice, (B) Immunofluorescent staining of VCAM-1 (CD106) within the 
intima and media region, (C-E) Double immunofluorescent staining of VCAM-1 (red stain) within 
endothelium (vWF) (green stain), macrophages (CD68) (green stain), and smooth muscle cells (SM 
actin) (geen stain). Yellow merge represents co-localization of VCAM-1 molecules with endothelium 
(vWF), macrophages (CD68), and smooth muscle cells (SMactin).  (F) Collagen deposition within the 
intimal and medial region. Representative images of histological examinations from n=3 mice, 
magnification x5. 
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4.2. Ex vivo validation studies of newly developed USPIO particles 
conjugated to the specific VCAM-1 binding peptide    
 
The second part of this thesis focused on determination of newly developed ultrasmall 
superparamagnetic iron oxide (USPIO) particles conjugated to VCAM-1 peptide (P03011) 
as a potential agent for visualization and monitoring the VCAM-1 expression within the 
immune cells involved in the pathogenesis of atherosclerosis. Non-conjugated USPIOs 
were also utilized as control particles for evaluation of particle unspecific binding. The 
structure of the non- and targeted iron oxide nanoparticles was demonstrated by electron 
microscopy, their superparamagnetic characteristics by magnetic resonance measurement 
at 17.6T MR system. The optimal injection dose of USPIO-VCAM-1 and USPIO was 
determined in MR experiments of ex vivo agar phantoms of atherosclerotic root region. 
The assessment of imaging time and pharmacokinetic analysis as well as biodistribution 
studies were performed by inductively coupled plasma emission spectroscopy and 
histology. 
 
4.2.1. Characterization of USPIO conjugated to the VCAM-1 peptide 
 
The synthetized 5 nm iron core of ultrasmall superparamagnetic iron oxide particles 
possessed a layer which consisted of gem-bisphosphonate compounds (CH(PO3H2)2)n that 
covered the particles (Patent number WO2004/058 275, US 2004/253181, Guerbet 
Research France). The particle covering layer of gem-bisphosphonate compounds was 
either conjugated to the specific cyclic VCAM-1 peptide via a carboxylate (RCOO-) group 
(USPIO-VCAM-1) or not (USPIO). Both of the particles were stabilized with the 
polyethylene glycol (PEG) chain (Patent number WO2004/058 275, US 2004/253181, 
Guerbet Research France). The diameter of the ultrasmall superparamagnetic iron oxide 
particles was 26 nm and the iron particle size, its dispersion property with (USPIO-
VCAM-1) or without (USPIO) vascular cell adhesion molecule-1 binding peptide was 
assessed by electron microscopy. The iron oxide USPIO-VCAM-1 (P03011) as well as 
USPIO (P3007) particle demonstrated homogenous dispersion and spherical size. Both of 
nanoparticles maintained and preserved stability in the solution (Figure 4.7). 
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Figure 4.7. The structure of USPIO-VCAM-1 (P03011) and control USPIO (P3007) contrast 
agent demonstrated by electron microscopy. Representative images n= 2. Scale bar is around 1 µm.  
After verification of the iron oxide structure, USPIO-VCAM-1 (P03011) and USPIO 
(P3007) contrast agents were further measured at 17.6 T MR system in order to test the 
superparamagnetic characteristics of both nanoparticles. Measurement of iron oxide T2 
relaxation time and fitted T2 map at different concentration of iron oxide enabled to 
establish the relaxivity rate (r2) which constituted at 98 mM-1 s-1 (Figure 4.8 A-B). In the 
presence of the gradually increasing concentration of iron oxide (Fe) contrast agent the 
measured relaxivity rate (r2) raised linearly (Figure 4.8 A-B).   
 
    
Figure 4.8. (A) T2 map at different concentration of iron oxide particles. (B) The relaxivity rate 
(r2) of USPIO particles measured at 17.6 T MR System in the presence of increasing amount of 
iron particles. 
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4.2.2. Half-life time of USPIO particles conjugated to the VCAM-1 peptide 
 
As USPIO-VCAM-1 as well as USPIO nanoparticles were newly developed for in vivo 
animal application, pharmacokinetic analyses of both components in the control C57Bl/6 
and ApoE-/- mice were conducted subsequently. Half-life time assessment of USPIO-
VCAM-1 (P03011) and control USPIO (P3007) particles was calculated by measuring the 
blood clearance before and after injection of both nanoparticles by inductively coupled 
plasma emission spectrometry (ICP-ES). Serum samples, which were collected before the 
injection of USPIO-VCAM-1 and control USPIO from the healthy control C57Bl/6 and 
atherosclerotic ApoE-/- mice, were measured firstly. The analyzed serum samples prior to 
the injection of both nanoparticles revealed no detectable iron content. Further the serum 
samples from the intravenously injected control and atherosclerotic ApoE-/- mice treated 
with either USPIO-VCAM-1 or USPIO alone were examined at 30 minutes, 2 hours, 5 
hours, and 24 hours. The concentration of iron particles in the collected serum samples of 
ApoE-/- mice at 30 minutes after 600 μmol/kg dose of USPIO-VCAM-1 (P03011) 
application was calculated to be around 598.23±124.4 mg iron/L. The iron content in the 
serum samples of ApoE-/- mice analyzed at 24 hours post USPIO-VCAM-1 (600 μmol/kg) 
injection reverted virtually to the base line with the iron concentration of 10.44±2.88 mg 
iron/L. The measured clearance of the iron oxide from the blood samples of ApoE-/- mice at 
the different time points enabled the assessment of the half-life time of USPIO-VCAM-1 
contrast agent, which was calculated to be about 4±2.4 hours in ApoE-/- mice (Figure 4.9). 
      
Figure 4.9. Serum concentration of iron oxide particles measured as mg/L prior and 30 minutes, 
2 hours, 5 hours, and 24 hours after intravenous injection of USPIO-VCAM-1 (P03011) agent in 
the ApoE
-/-
 mice (n=5). The estimation of iron oxide was performed via ICP-ES measurement.  
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In contrast, the measured serum sample of USPIO-VCAM-1 injected control C57Bl/6 mice 
(600 μmol/kg) after 30 minutes post-injection showed the iron content of around 
715.54±53.21 mg iron/L. The iron content in the serum sample of control mice was 
roughly cleared with the calculated value of 75.48±21.1 mg iron/L within 24 hours. 
       
Figure 4.10. Serum concentration of iron oxide (Fe) particles measured as mg/L prior and 30 
minutes, 2 hours, 5 hours, and 24 hours after intravenous injection of USPIO-VCAM-1 
(P03011) agent in the control C57Bl/6 mice. The estimation of iron oxide was performed via ICP-
ES measurement (n=5).  This figure was published in a similar format in (Michalska, Machtoub et al. 
2012). 
The estimated half-life time of USPIO-VCAM-1 particles in the control group of C57Bl/6 
mice was 7.2±2.5 hours (Figure 4.10). The pharmacokinetic analyses of iron clearance 
from ApoE-/- mice injected with 600 μmol/kg of USPIO (P3007) demonstrated the high 
iron content in the serum samples collected after 30 minutes post-injection and resulted in 
the concentration of 660.62±8.8 mg iron/L. The high USPIO iron oxide amount was 
cleared from the blood stream within 24 hours and reverted to the level of 21.94±8.03 mg 
iron/L. The calculated half-life time of USPIO in ApoE-/- mice was 6.0±1.3 hours (Figure 
4.11). 
67 
 
      
Figure 4.11. Serum concentration of iron oxide (Fe) particles measured as mg/L prior and 30 
minutes, 2 hours, 5 hours, and 24 hours after intravenous injection of USPIO (P3007) agent in 
the atherosclerotic ApoE
-/- 
mice. The estimation of iron oxide was performed via ICP-ES 
measurement (n=5).  This figure was published in a similar format in (Michalska, Machtoub et al. 
2012). 
In control C57Bl/6 mice the analyzed iron content in the serum samples after 30 minutes 
post 600 μmol/kg of USPIO (P3007) injection was about 792.16±196.83 mg iron/L. After 
24 hours the iron concentration within the serum samples of control mice decreased to the 
level of 53.26±21.4 mg iron/L. The half-life time of USPIO in the control C57Bl/6 mice 
was calculated to be about 5.0±1.7 hours (Figure 4.12).   
      
Figure 4.12. Serum concentration of iron oxide (Fe) particles measured as mg/L prior and 30 
minutes, 2 hours, 5 hours, and 24 hours after intravenous injection of USPIO (P3007) agent in 
the control C57Bl/6 mice. The estimation of iron oxide was performed via ICP-ES measurement 
(n=5).  This figure was published in a similar format in (Michalska, Machtoub et al. 2012). 
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 The assessment of USPIO-VCAM-1 (P03011) and USPIO (P3007) particles 
clearance enabled to estimate the optimal in vivo imaging time. Due to the fact that 
USPIO-VCAM-1 and USPIO particles were cleared from the blood stream within 24 
hours, the control C57Bl/6 and ApoE-/- animals were intended for MR imaging pre and 24 
hours post contrast agent application.   
 
4.2.3. Biodistribution of USPIO particles conjugated to the VCAM-1 peptide 
 
Following the completion of pharmacokinetics studies, the biodistribution was performed. 
The localization of USPIO-VCAM-1 and USPIO particles within the excised organs as 
liver, lungs, spleen, lymph nodes, kidneys, brain, and muscle from control C57Bl/6 and 
ApoE-/- mice was determined by Prussian Blue staining. Young and old ApoE-/- mice were 
injected with 600 μmol/kg dose of USPIO-VCAM-1 (P03011) particles and excised organs 
were analyzed pre and 24 hours post particle application. The ApoE-/- mice injected with 
USPIO-VCAM-1 demonstrated massive amount of iron oxide nanoparticles within the 
liver and the spleen (Figure 4.13 A-C). The positions where these particles were 
distributed were mostly associated to macrophages within the whole liver and the splenic 
red pulp (Figure 4.13 A). P03011 particles were also identified histologically in the lymph 
node especially within subcapsular sinus and in the cortex and medulla region of the 
kidneys (Figure 4.13 B). Additionally to that, lungs, brain, and skeletal muscles were free 
from iron particles (Figure 4.13 C). The same results were observed within the group of 
control C57Bl/6 mice injected with 600 μmol/kg dose of USPIO-VCAM-1 particles (data 
not shown).  
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Figure 4.13. Distribution of USPIO-VCAM-1 particles within dissected organs from ApoE
-/- 
mice. (A, B) While not found before injection, iron oxide particles were localized to macrophages 
within the liver, and spleen, as well as within the lymph nodes and the kidneys. (C) There was no iron 
deposition in the lung, skeletal muscle or brain. Representative images from n= 6. This figure was 
published in a similar format in (Michalska, Machtoub et al. 2012).  
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In contrast, injection of 600 µmol/kg dose of USPIO particles resulted in iron 
accumulation mostly within the liver and the spleen of young and old ApoE-/- mice 
analyzed 24 hours post contrast agent application (Figure 4.14 A). There was no iron 
particles observed within the lymph nodes, kidneys, skeletal muscles, lungs, or brain 
(Figure 4.14 B). Control USPIO injected C57Bl/6 mice (600 μmol/kg dose) emerged the 
same findings as USPIO injected ApoE-/- mice (data not shown). 
  
Figure 4.14. (A) Localization of USPIO particles within the liver and spleen of ApoE
-/- 
mice. (B) There 
was no iron deposition in the kidneys, lung, skeletal muscle or brain. Representative images from n= 6.   
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4.2.4. Ex vivo dose-dependent evaluation of USPIO-VCAM-1 for in vivo application 
 
Feasibility of USPIO-VCAM-1 contrast agent application together with control USPIO 
particles was investigated via ex vivo MR measurement of the agar phantoms containing 
aortic root regions from control C57Bl/6 and atherosclerotic ApoE-/- mice. Initially agar 
phantoms of aortic root region from non-injected control and atherosclerotic mice were 
measured. The non-injected agar phantoms of aortic roots from control C57Bl/6 as well as 
ApoE-/- mice demonstrated no darkening within aortic wall (Figure 4.15). 
     
Figure 4.15. T2-weighted images of ex vivo agar phantoms of aortic root regions from control 
C57Bl/6 and ApoE
-/-
 mice (n=3). T2 map of control and atherosclerotic root region signified the T2 
time of 120 milliseconds. 
Further there was dose-dependent study of USPIO-VCAM-1 and USPIO performed. These 
experiments were planned in order to determine optimal injection dose that could assure 
the best MR contrast visible in vivo. The dose of 100, 300, and 600 µmol/kg dose of 
USPIO-VCAM-1 and USPIO was in vivo applied into ApoE-/- mice and the aortic root 
regions were further excised after 24 hours and MR measured. Ex vivo MR measurements 
of aortic root regions from ApoE-/- mice injected with either 100 or 300 µmol/kg dose 
emerged no significant alterations. The calculated T2 maps from these phantoms 
confirmed and pointed the similar T2 time of 100 milliseconds as in the case of non-
injected control and ApoE-/- mice. However the injection of 600 µmol/kg dose of USPIO-
VCAM-1 particles demonstrated significant signal loss within the atherosclerotic lesions of 
aortic wall pointing also the decline in T2 relaxation time from 100 to 10 milliseconds 
(Figure 4.16). 
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Figure 4.16. T2-weighted images of aortic root from USPIO-VCAM-1 injected ApoE
-/-
 mice 
(n=3). The ex vivo measurements were conducted 24 hours after contrast agent application and have 
indicated significant darkening within the aortic wall after injection of 600 µmol/kg dose.  
As the dose of 600 µmol/kg USPIO-VCAM-1 particles, examined after 24 hours, 
demonstrated significant signal loss within the aortic roots of ApoE-/- mice measured in 
agar phantoms, this dose was selected for all subsequent ex vivo and in vivo MR 
experiments.  
 
4.2.5. Ex vivo determination of early and advanced lesions by newly developed USPIO 
particles conjugated to the VCAM-1 peptide 
 
To test the USPIO-VCAM-1 specific binding to vascular cell adhesion (VCAM-1) 
molecules expressed within early and advanced inflamed lesions, aortae from 12 and 30 
week old healthy control C57Bl/6 and ApoE-/- mice were excised and investigated as next. 
Ex vivo MR measured agar phantoms of aortic root region from 12 and 30 week old 
C57Bl/6 mice, excised 24 hours after intravenous injection of 600 µmol/kg dose of 
USPIO-VCAM-1, indicated no signal loss within the aortic wall (data not shown). 
Whereas ex vivo agar phantoms of atherosclerotic root regions from young and old ApoE-/- 
mice, injected with USPIO-VCAM-1 and analyzed after 24 hours, revealed significant 
alterations. The group of 12 week old ApoE-/- mice injected with 600 µmol/kg dose of 
USPIO-VCAM-1 particles were examined first and the ex vivo MR measurements of the 
young atherosclerotic roots demonstrated significant partial darkening associated with the 
contrast agent injection (Figure 4.17 A). The ex vivo T2-weighted MR images of agar 
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phantoms from 30 weeks old ApoE-/- mice injected with 600 µmol/kg dose of USPIO-
VCAM-1 particles revealed very strong signal loss within the whole aortic root region of 
advanced plaques (Figure 4.17 B). 
      
Figure 4.17. T2-weighted images of aortic root from USPIO-VCAM-1 injected 12 and 30 week 
old ApoE
-/- 
mice (n=3). Significant signal loss within aortic root of (A) 12 week old and (B) 30 week 
old ApoE
-/-
 mice injected with 600 µmol/kg USPIO-VCAM-1 particles. 
 
While not observed in the healthy control group of C57Bl/6 mice, 600 µmol/kg dose of 
newly developed USPIO-VCAM-1 contrast agent enabled firstly ex vivo detection of the 
early and advanced inflammatory process within the aortic root from 12 and 30 week old 
ApoE-/- mice by MR imaging. Further ex vivo T2-weighted images of USPIO-VCAM-1 
injected ApoE-/- mice allowed observing the thickening process of the arterial wall. The 
MR measurements were compared with the histological observations from the 12 and 30 
week old ApoE-/- mice and confirmed these findings (Figure 4.18 A-D). 
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Figure 4.18. Histological and MR assessment of the inflammation within early and advanced 
lesions from atherosclerotic ApoE
-/-
 mice (n=3). (A) Morphology and VCAM-1 expression (red 
stain) within the aortic root of the young plaques from 12 week old ApoE
-/-
 mice, (B) T2-weighted 
image of aortic root from 12 week old ApoE
-/- 
mice measured after USPIO-VCAM-1 application, (C) 
Morphology and VCAM-1 expression within the aortic root of the advanced plaques from 30 week 
old ApoE
-/-
 mice, (D) T2-weighted image of aortic root from 30 week old ApoE
-/- 
mice measured after 
USPIO-VCAM-1 injection. 
Application of USPIO-VCAM-1 particles into 12 week old ApoE-/- mice revealed a 
significant partial signal loss within the aortic wall observed on T2-weighted images, in 
areas where strong VCAM-1 expression was detected via histology (Figure 4.18 A-B). In 
the group of 30 week old ApoE-/- mice, application of USPIO-VCAM-1 particles 
demonstrated strong and significant darkening within the arterial wall. The signal loss 
observed on T2-weighted ex vivo MR images of advanced lesions was correlated with the 
strong and expanded VCAM-1 expression within intima and media of atherosclerotic 
aortic wall presented by histological staining. With the help of ex vivo MR images and 
histology it was feasible to localize the USPIO-VCAM-1 particles within the early and 
advanced lesions where the VCAM-1 expression was detected and further estimate the 
thickness of the aortic wall within the 12 and 30 week old ApoE-/- mice (Figure 4.18 B, D).  
 As next USPIO contrast agent was examined ex vivo and compared to USPIO-
VCAM-1 particles within the group of healthy control C57Bl/6 as well as 12 and 30 week 
old ApoE-/- mice. Ex vivo MR measurements of agar phantoms containing aortic roots of 12 
and 30 week old healthy control C57Bl/6 mice showed no signal loss after application of 
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600 µmol/kg dose of USPIO particles (data not shown). The agar phantoms containing 
aortic root regions of 12 week old ApoE-/- mice, measured 24 hours post 600 µmol/kg dose 
of USPIO injection, indicated no alterations within the aortic wall (Figure 4.19 A). Only 
application of USPIO particles into 30 week old ApoE-/- mice demonstrated mild signal 
alterations within aortic root detected on T2-weighted ex vivo images (Figure 4.19 B).   
       
Figure 4.19. T2-weighted images of aortic root from USPIO injected 12 and 30 week old ApoE
-/- 
mice (n=3). (A) No alteration observed within aortic root of 12 week old and (B) mild signal loss 
within aortic root of 30 week old ApoE
-/- mice injected with 600 µmol/kg dose of USPIO particles. 
 
Comparing non- and targeted approach, USPIO-VCAM-1 particles visualized significantly 
early and advanced lesions of 12 and 30 week old ApoE-/- mice ex vivo. In contrast, USPIO 
particles did not provide with notable results. Application of USPIO particles did not allow 
to assess early lesions of 12 week old ApoE-/- mice ex vivo. Within advanced plaques 
USPIOs caused the darkening however the signal loss was not significant when compared 
to detected USPIO-VCAM-1 particles (Figure 4.20). 
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Figure 4.20. Visualization of the early and advanced atherosclerotic plaques from 12 and 30 
week old ApoE
-/- 
mice (n=3). (A) T2-weighted MR images of 12 week old ApoE
-/-
 mice injected with 
either USPIO-VCAM-1 or USPIO particles, (B) T2-weighted MR images of 30 week old ApoE
-/-
 mice 
injected with either USPIO-VCAM-1 or USPIO particles. 
 
4.3. In vivo application of newly developed iron oxide nanoparticles    
 
After completion of ex vivo validation studies on iron oxide nanoparticles conjugated with 
(USPIO-VCAM-1) or without (USPIO) specific cyclic VCAM-1 peptide, both of 
nanoparticles were implemented and tested in vivo. These experiments were designed in 12 
and 30 week old healthy control C57Bl/6 and atherosclerotic ApoE-/- mice and performed 
at 17.6 T ultra-high magnetic field. 
 
4.3.1. In vivo determination of early and advanced lesions by newly developed USPIO 
conjugated to the VCAM-1 peptide 
 
Ex vivo experimental part on USPIO-VCAM-1 and USPIO particles allowed firstly to 
assess the structure of iron oxide nanoparticles, their superparamagnetic characteristics, 
and further to establish the half-life time for optimal imaging time, and the most favorable 
injection dose. As dose of 600 µmol/kg iron oxide USPIO-VCAM-1 particles gave the best 
appreciable contrast and significant signal loss within the aortic root of 12 and 30 week old 
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ApoE-/- mice, observed in ex vivo MR experiments, this dose was implemented in all in 
vivo MR experiments. Applied 600 µmol/kg dose of control non-targeted USPIO particles 
revealed non-significant and only light darkening within aortic root of 30 week old ApoE-/- 
mice in ex vivo MR measured agar phantoms. In spite of that, USPIO particles were also 
applied in in vivo experiments and compared with the results obtained from targeted 
USPIO-VCAM-1 particles.  
 Prior to the final in vivo MR examination of control C57Bl/6 and ApoE-/- mice, the in 
vivo preliminary MR trial was conducted in order to verify optimal in vivo MR imaging 
time with that proposed by pharmacokinetic data. As first the group of control C57Bl/6 
mice was injected with 600 µmol/kg dose of USPIO-VCAM-1 and USPIO contrast agent 
and analyzed at 1 hour, 6 hours, and 24 hours by ultra-high MRI. Regarding to the 
pharmacokinetic data (Figure 4.10 and 4.12) both of the nanoparticles circulated in the 
blood stream at 1 hour and 6 hours. It was also difficult to obtain the clear MR image of 
the whole aorta as well as of the aortic root region at that time. In both cases, USPIO-
VCAM-1 and USPIO content declined from the blood within 24 hours and at this time 
point high signal to noise image of the whole aorta and the aortic root was obtained using 
FLASH MR sequence (Figure 4.10 and 4.12, data not shown). Good correlation between 
in vivo MRI and pharmacokinetic analyses (Figure 4.9 and 4.11) was also observed within 
the group of ApoE-/- mice. In vivo MRI, acquired 1 hour post 600 µmol/kg dose of USPIO-
VCAM-1, hindered to image aorta and aortic root region (Figure 4.21). 
    
Figure 4.21. In vivo MR T2*-weighted images of aortic root region from ApoE
-/-
 mice (n=3) 
obtained via FLASH sequence (A) prior to and (B) 1 hour after injection of 600 µmol/kg 
USPIO-VCAM-1 particles.  
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Further MR acquisition of aorta and aortic root 6 hours post contrast agent application did 
not allow to visualize aorta without the noise (Figure 4.22). 
    
Figure 4.22. In vivo MR T2*-weighted images of aortic root region from ApoE
-/- 
mice (n=3) 
obtained via FLASH sequence (A) prior to and (B) 6 hours after injection of 600 µmol/kg 
USPIO-VCAM-1 particles. 
These initial findings gave the evidence that the best time for imaging was 24 hours, when 
all particles were cleared from the blood stream as confirmed by pharmacokinetics analysis 
(Figure 4.9 - 4.12, and Figure 4.23). 
    
Figure 4.23. In vivo MR T2*-weighted images of aortic root region from ApoE
-/- 
mice (n=3) 
obtained via FLASH sequence (A) prior to and (B) 24 hours after injection of 600 µmol/kg 
USPIO-VCAM-1 particles. 
After completion of the initial in vivo MR experiments, aorta and aortic roots pre and 24 
hours post injection of 600 µmol/kg USPIO-VCAM-1 and USPIO particles were 
visualized within 12 and 30 week old healthy control C57Bl/6 and ApoE-/- mice. Ultra-high 
resolved T2*-weighted images of the aortic root areas from healthy control C57Bl/6 mice 
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demonstrated no signal loss within the aortic wall pre and post injection of USPIO-
VCAM-1 particles (Figure 4.24 A - B). Signal intensity within the aortic root pre and 24 
hours post USPIO-VCAM-1 application in the 12 and 30 week old control C57Bl/6 mice 
was analyzed by calculating the SNR and CNR values. Signal to noise ratio (SNR) was 
defined as the signal intensity measured within the arterial wall (SI aortic wall) pre and 24 
hours post contrast agent injection. In addition to SNR, the CNR value was determined. 
Contrast to noise ratio (CNR) value characterized the signal intensity derived from the 
blood (SI blood) and aortic wall (SI aortic wall) pre and post contrast agent injection (detailed 
information described in Method chapter: 3.5.4. Data Analysis). The SNR as well as the 
CNR values within the 12 and 30 week old control group pre and post application of 
USPIO-VCAM-1 particles remained unaltered (Figure 4.29 A - B). 
    
Figure 4.24. In vivo ultra-high field MR images of 12 and 30 week old control C57Bl/6 mice. (A) 
T2*- weighted image of young 12 week old C57Bl/6 mice pre and 24 hours post USPIO-VCAM-1 
injection, (B) T2*-weighted image of 30 week old C57Bl/6 mice pre and 24 hours post USPIO-
VCAM-1 injection. Representative images from n= 6. Yellow arrows indicate aortic root region. 
The group of atherosclerotic ApoE-/- mice was analyzed as next. The intravenous injection 
of 600 µmol/kg dose of USPIO-VCAM-1 particles into 12 week old ApoE-/- mice with 
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early lesions showed the partial still significant signal loss within the aortic wall 
demonstrated on T2*-weighted MR images (Figure 4.25 A). The same significant but 
more intense observation was done within the group of 30 week old ApoE-/- mice with 
advanced plaques (Figure 4.25 B). This group of ApoE-/- mice treated with USPIO-
VCAM-1 particles presented notable darkening within the aortic root area.       
    
Figure 4.25. In vivo ultra-high field MR images of 12 and 30 week old ApoE
-/- 
mice. (A) T2*-
weighted image of young 12 week old ApoE
-/- 
mice pre and 24 hours post USPIO-VCAM-1 injection 
noticed as partial signal loss within arterial wall. (B) T2*-weighted image of 30 week old ApoE
-/-
 mice 
pre and 24 hours post USPIO-VCAM-1 injection detected as marked, darkening within the aortic 
wall. Representative images from n= 6. Yellow arrows indicate aortic root region. This figure was 
published in a similar format in (Michalska, Machtoub et al. 2012). 
The quantified SNR values of 12 and 30 week old ApoE-/- mice injected with USPIO-
VCAM-1 particles significantly declined when compared to the SNR values before 
injection (Figure 4.29 A). Additionally, the CNR values of 12 week old ApoE-/- mice 
pointed 2 fold alteration post USPIO-VCAM-1 injection and almost 3 fold increase in 30 
week old ApoE-/- mice treated with targeted particles. As the signal variations increased 
within aortic root region 24 hours post USPIO-VCAM-1 injection, the CNR values 
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remained positive (Figure 4.29 B). The SNR and CNR semi-quantification highlighted the 
relevance of detected signal loss within the early and advanced lesions of 12 and 30 week 
old ApoE-/- mice injected with USPIO-VCAM-1 contrast agent. In addition, the analysis of 
ex vivo and in vivo results correlated well and revealed the same findings (Figure 4.26). 
The extent of the signal loss associated with the application of targeted USPIO-VCAM-1 
particles was slight within the early lesions detected by ex vivo and in vivo MR 
experiments (Figure 4.26 A). The in vivo signal loss pattern post USPIO-VCAM-1 
injection appeared stronger and was more excessive within the advanced lesions also 
confirmed by ex vivo MR results (Figure 4.26 B).   
     
Figure 4.26. Determination of the inflammatory process within early and advanced plaques by 
USPIO-VCAM-1 particles. (A) Ex vivo (n=3) and in vivo (n=6) MR images of partial signal loss 
within the aortic root region of early lesions detected by application of targeted iron oxide 
nanoparticles. (B) Ex vivo (n=3) and in vivo (n=6) MR images of intensive darkening within the aortic 
root of advanced lesions detected by application of USPIO-VCAM-1. Yellow arrows indicate aortic 
root region.  
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The use of targeted iron oxide USPIO-VCAM-1 contrast agent revealed interesting results 
within the group of 12 and 30 week old ApoE-/- mice and led to assessment of the early and 
advanced plaques. To check the specificity of applied USPIO-VCAM-1 and to verify the 
significance of obtained ex vivo and in vivo results, USPIO particles were also tested and 
applied in vivo. Control 12 and 30 week old C57Bl/6 mice were analyzed pre and 24 hours 
post 600 µmol/kg dose of USPIO injection as first. In vivo application of non-targeted 
USPIO particles emerged no darkening within aortic root of healthy control mice (Figure 
4.27). The calculated SNR and CNR values from young and old control C57Bl/6 mice pre- 
and post-USPIO administration remained unchanged (Figure 4.29 A, B).   
    
Figure 4.27. In vivo ultra-high field MR images of 12 and 30 week old control C57Bl/6 mice. (A) 
T2*-weighted image of young 12 week old C57Bl/6 mice pre and 24 hours post USPIO injection, (B) 
T2*-weighted image of 30 week old C57Bl/6 mice pre and 24 hours post USPIO injection. 
Representative images from n= 6. Yellow arrows indicate aortic root region. 
Injection of 600 µmol/kg dose of non-targeted USPIO into 12 week old ApoE-/- mice 
showed no signal alteration within the aortic wall compared to non-injected mice and was 
unsuccessful to detect the early changes (Figure 4.28 A). In addition, application of 
USPIO particles into the group of 30 week old ApoE-/- mice manifested only slight and 
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mild signal loss within the aortic root areas (Figure 4.28 B). Quantified SNR and CNR 
values pre and post injection of USPIO particles indicated non-significant signal change 
within the early and advanced lesions of 12 and 30 week old ApoE-/- mice (Figure 4.29 A, 
B). 
    
Figure 4.28. In vivo ultra-high field MR images of the 12 and 30 week old ApoE
-/-
 mice. (A) T2*-
weighted image of aortic root of 12 week old ApoE
-/-
 mice pre and 24 hours post application of 600 
µmol/kg dose of USPIO particles, (B) T2*-weighted image of aortic root of 30 week old ApoE-/- mice 
pre and 24 hours post injection of 600 µmol/kg dose of USPIO particles. Slight and non-significant 
darkening observed within aortic wall after injection of 600 µmol USPIO particles into 30 week old 
ApoE
-/- 
mice. Representative images from n=6. Yellow arrows indicate aortic root region. This figure 
was published in a similar format in (Michalska, Machtoub et al. 2012). 
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Figure 4.29. Semi-quantitative assessment of signal alteration pre and post application of 
USPIO-VCAM-1 and USPIO particles. Representation of (A) signal to noise ratio (SNR) and (B) 
contrast to noise ratio (CNR) value within aortic root region of control C57Bl/6 and ApoE
-/- 
mice (n=6 
/ group) treated with USPIO-VCAM-1 or USPIO particles. Significant signal alteration within aortic 
wall of control and atherosclerotic mice pre and pos t contrast agent application presented via 1-way 
ANOVA test when P<0.05, ns (nonsignificant). This figure was published in a similar format in 
(Michalska, Machtoub et al. 2012). 
 
 In vivo conducted MR experiments within the 12 and 30 week old ApoE-/- mice 
demonstrated the feasibility of targeted iron oxide particles USPIO-VCAM-1 to detect 
early and advanced plaques. USPIO-VCAM-1 successfully visualized ex vivo and in vivo 
inflammatory changes within the aortic wall of atherosclerotic mice and further enabled 
monitoring the plaque progression by imaging the vascular adhesion molecules. In 
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contrast, USPIO particles were unable to monitor early lesions and showed ex vivo and in 
vivo only modest alterations within the group of 30 week old ApoE-/- mice. Thus targeted 
USPIO conjugated to the specific VCAM-1 peptide presented promising contrast agent for 
monitoring of early and advanced inflammatory process of atherosclerosis.    
 
4.4. Cellular localization of USPIO conjugated to the VCAM-1 peptide 
 
The last part of this study investigated the localization of iron oxide particles conjugated to 
the VCAM-1 peptide within the diverse immune cells involved in the early and advanced 
lesion formation. As the USPIO-VCAM-1 aimed to target the vascular cell adhesion 
molecules, its co-localization within the cells expressing VCAM-1 was further examined. 
The analysis of iron distribution was conducted via electron microscopy and histology 
using Prussian Blue and immunofluorescent staining.  
 
4.4.1. Distribution of USPIO conjugated to the VCAM-1 peptide 
 
Localization of iron oxide nanoparticles was examined by Prussian Blue staining. USPIO-
VCAM-1 particles were found not only in the luminal region of the formed plaques but 
also deeper in the intimal areas of the fibrous cap and plaque shoulders of 12 and 30 week 
old ApoE-/- mice. Moreover iron particles were also found within the border line to the 
media. The adjacent sections from the Prussian Blue stained aortic root areas were further 
analyzed and immune-stained for VCAM-1 expression. The immune VCAM-1 staining of 
these sections revealed the findings that in the atherosclerotic root regions of USPIO-
VCAM-1 treated ApoE-/- mice, where the iron oxide particles were detected, the strong 
VCAM-1 expression was present (Figure 4.30). The manifestation of VCAM-1 expression 
within the early and advanced plaques of 12 and 30 week old ApoE-/- mice was strong and 
extensive (Figure 4.30, Figure 4.3 B, Figure 4.6 B). 
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Figure 4.30. Co-localization of iron oxide particles with the VCAM-1 staining within the 
atherosclerotic lesions of ApoE
-/- 
mice treated with USPIO-VCAM-1 contrast agent. (A) Prussian 
Blue stained regions of aortic root demonstrated the iron particles within the lumina l areas, intima and 
within the border to the medial regions (pointed by arrows, magnification x40), (B) VCAM-1 red 
staining of aortic root within lumen, intima and media (pointed by arrows, magnification x40). L- 
lumen, I- intima, M- media. Representative images from n=6 mice. This figure was published in a 
similar format in (Michalska, Machtoub et al. 2012). 
 
In contrast, Prussian Blue staining of 12 and 30 week old ApoE-/- mice injected with 
USPIO alone demonstrated no detectable iron within the arterial wall of aortic root (Figure 
4.31 A, B). Additionally to the 12 and 30 week old USPIO injected ApoE-/- mice, 
application of either USPIO or USPIO-VCAM-1 into healthy control C57Bl/6 mice 
emerged no iron within the aortic root regions (data not shown). These histological 
findings evidenced that the significant signal loss observed ex vivo and in vivo within the 
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aortic roots of 12 and 30 week old ApoE-/- mice was only associated with application of 
USPIO-VCAM-1 particles. 
   
Figure 4.31. Prussian Blue staining of early and advanced plaques from (A) 12 and (B) 30 week 
old ApoE
-/-
 mice injected with USPIO particles  (magnification x40). Representative images from 
n=3 mice. 
 
As USPIO-VCAM-1 particles were detected in the aortic root regions of 12 and 30 week 
old ApoE-/- mice where the endothelial cells, smooth muscle cells and macrophages were 
present, the double staining of these cells with VCAM-1 was planned subsequently. The 
immune staining was performed in the adjacent sections to the Prussian Blue stained 
regions to verify whether these immune cells, where the iron particles were found, express 
vascular cell adhesion molecules. Double staining of VCAM-1 (CD106) with endothelial 
cells (vWF), VCAM-1 with macrophages (CD68) and VCAM-1 with smooth muscle cells 
(α smooth muscle cell actin) emerged that all of these cells possessed VCAM-1 expression 
(Figure 4.32 and Figure 4.33) as also demonstrated in earlier double immunofluorescent 
experiments (Figure 4.3 B-E and Figure 4.6 B-E). In addition, Prussian Blue together 
with double immune staining confirmed the USPIO-VCAM-1 particle specific binding to 
the regions owning extensive VCAM-1 expression not only within the intimal endothelial 
cells but also within smooth muscle cells and macrophages and further within the medial 
smooth muscle cells throughout the early and advanced plaques (Figure 4.32 A-C, Figure 
4.33 A-B).   
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Figure 4.32. Co-localization of USPIO-VCAM-1 particles within the cells expressing vascular 
cell adhesion molecules in the aortic wall of ApoE
-/-
 mice. (A, C) Distribution of iron particles 
within the intimal and medial immune cells (indicated by arrows, magnification of x20). (A, B, C) 
VCAM-1 molecules (red stain) appeared in the regions of plaque endothelial (vWF) (green stain) and 
smooth muscle (SMC) cells (green stain) where USPIO-VCAM-1 particles were found (magnification 
x40), L- lumen, I- intima, M- media. Yellow merge represents co-localization of VCAM-1 molecules 
with endothelium (vWF) and smooth muscle cells  (SMC). This figure was published in a similar 
format in (Michalska, Machtoub et al. 2012). 
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Figure 4.33. Co-localization of USPIO-VCAM-1 particles within the cells expressing vascular 
cell adhesion molecules in the aortic wall of ApoE
-/-
 mice. (A, B) Distribution of iron particles 
within the intimal and medial immune cells (indicated by arrows, magnification of x20), (A) VCAM-1 
expression (red stain) localized within the plaque macrophages (CD68) (green stain) where USPIO-
VCAM-1 particles were found (magnification x40), (B) VCAM-1 molecules (red stain) appeared in 
the region of medial smooth muscle cells (SMC) (green stain) and in this region USPIO-VCAM-1 
particles were found (magnification x40), L- lumen, I- intima, M- media. Yellow merge represents co-
localization of VCAM-1 molecules with macrophages (CD68) and smooth muscle cells  (SMC). 
While USPIO-VCAM-1 particles were found within the VCAM-1 positive cells as intimal 
endothelial and smooth muscle cells, and macrophages, the Prussian Blue staining of 
medial plaque region revealed only modest detectable iron deposition despite very strong 
expression of vascular cell adhesion molecules within medial smooth muscle cells. One 
drawback of Prussian Blue staining is low sensitivity, therefore supplementary experiments 
were performed in order to investigate the exact localization of targeted iron oxide 
nanoparticles within intima and media. Additionally to the histological assessment of 
USPIO-VCAM-1 distribution, electron microscopy was conducted in the adjacent section 
of the Prussian Blue stained aortic root regions. Electron microscopy further examined 
whether the iron oxide particles conjugated to the VCAM-1 specific peptide were located 
extra- or intracellular. The analyses of USPIO-VCAM-1 injected 12 and 30 week old 
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ApoE-/- mice demonstrated iron particles within the intima, enclosed in the large 
endosomes of the endothelial cells, as well as in the extracellular matrix between the 
smooth muscle and endothelial compartments. Further electron microscopy localized iron 
oxide particles within the surface of the intimal smooth muscle cells and in the medial 
smooth muscle cells’ regions rich in collagen filaments (Figure 4.34). 
  
Figure 4.34. Electron microscopy image of aortic root section from USPIO-VCAM-1 injected 
ApoE
-/-
 mice (n=2). (A) USPIO-VCAM-1 particles were detected within the intimal endothelial cells 
(E) as well as intimal smooth muscle cells (SMC) and in the extracellular matrix (EM).  (B) Medial 
region revealed accumulation of USPIO-VCAM-1 particles within collagen filaments (iron particles 
pointed by arrows, scale bar 1 μm). (Michalska, Machtoub et al. 2012) 
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5. Discussion 
 
Vascular cell adhesion molecules have an enormous function within the early and 
advanced atherosclerotic plaques (Huo and Ley 2001; Ley and Huo 2001; Libby 2002; 
Blankenberg, Barbaux et al. 2003). They emerge before the onset of atherosclerotic lesions 
and control the whole chronic inflammatory process of atherosclerosis by accelerating the 
leukocytes’ recruitment (Iiyama, Hajra et al. 1999; Huo and Ley 2001; Libby, Ridker et al. 
2002). They are expressed on endothelial cells only in the face of inflammation at the 
atheroma-prone sites initiating subsequent alterations within the arterial wall (Nakashima, 
Raines et al. 1998; Cybulsky, Iiyama et al. 2001; Huo and Ley 2001; Ley and Huo 2001; 
Libby 2002). Their exceptional expression pattern and significance in the origin of 
atherosclerosis has been shown by diminished plaque growth in the genetically modified 
mouse model lacking VCAM-1 gene (Cybulsky, Iiyama et al. 2001; Libby 2002; Libby, 
Ridker et al. 2002). Lesion formation in ApoE-/- mouse models represents similar 
morphology to those found in human plaques (Nakashima, Plump et al. 1994; Iiyama, 
Hajra et al. 1999; Pendse, Arbones-Mainar et al. 2009). As with ApoE-/- mouse models, 
VCAM-1 molecules appear early in the human atherosclerotic lesions, initiating leukocyte 
recruitment from aortic lumen and further promoting enhanced leukocyte invasion from 
new microvessels of the adventitia region in advanced plaques (Davies, Gordon et al. 
1993; O'Brien, Allen et al. 1993). Hence, VCAM-1 is a compelling marker for the early as 
well as advanced inflammatory alterations within the affected arterial wall in both animal 
models and humans (Libby 2002). Therefore, selection and targeting of VCAM-1 
molecules would allow monitoring of the inflammation, and would further help to establish 
early prevention of atherosclerosis (Blankenberg, Barbaux et al. 2003) before the origin of 
the thrombus formation, of which late recognition leads to myocardial infarction.  
 Exactly this work presented the VCAM-1 concept as a suitable approach to monitor 
early alterations and advanced lesions of atherosclerosis. This thesis involved ex vivo and 
in vivo experiments and was divided into four parts. In the first part (described in the 
chapter: 5.1. Vascular adhesion molecules (VCAM-1) participate in early lesion formation 
and promote plaque growth), this study demonstrated the early and advanced plaque 
alterations and localization of immune cells enrolled in the intimal and medial region of the 
aortic wall of 12 and 30 week old atherosclerotic ApoE-/- mice. Among investigation of 
plaque immune cell distribution, vascular cell adhesion (VCAM-1) expression was 
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examined and proven to emerge within the involved immune plaque cells. Hence it 
indicated the substantial role of VCAM-1 molecules not only in early but also in advanced 
lesions. These important findings of the first part of this thesis influenced the decision of 
selecting VCAM-1 as an excellent marker for monitoring the atherosclerotic lesions in the 
established murine atherosclerotic model. In the second and third part (described in the 
chapter: 5.2. USPIO conjugated to VCAM-1 cyclic peptide detects early and advanced 
lesions ex vivo and 5.3. USPIO conjugated to VCAM-1 cyclic peptide detects early and 
advanced lesions in vivo and monitors inflammation), this thesis showed the proof of 
principle and capability of the newly designed iron oxide contrast agent functionalized 
with the cyclic peptide specific for VCAM-1 recognition. The experimental validation 
studies including ultra-high MRI enabled further ex vivo and in vivo detection of applied 
USPIO-VCAM-1 (P03011) particles within the aortic root region of early and advanced 
atherosclerotic plaques. In the last part (described in the chapter: 5.4. USPIO conjugated to 
VCAM-1 cyclic peptide localizes within the plaque cells expressing VCAM-1), this thesis 
illuminated and proved by histology and electron microscopy that USPIO-VCAM-1 
particles specifically targeted VCAM-1 molecules and accumulated within plaque cells. 
Concluding, the newly designed USPIO-VCAM-1 particles presented in this thesis gave 
evidence that this functionalized approach offers a promising method for evaluation of 
early changes and advanced alterations of atherosclerosis. 
 
5.1. Vascular adhesion molecules (VCAM-1) participate in early lesion 
formation and promote plaque growth  
 
This study firstly evaluated the early and advanced alterations of the aortic wall of 12 and 
30 week old ApoE -/- mice. The group of 12 week old ApoE-/- mice, kept on a high fat diet 
for 8 weeks, already demonstrated small sized plaques with the initiated inflammatory 
process within endothelial cells, appearance of smooth muscle cells within intima, and 
mild recruitment of leukocytes within the atheroma-prone sites. The early lesions with 
characteristic cell infiltration presented a relentless face of activation. Plaque endothelial as 
well as macrophages demonstrated strong phagocytic activity and deposited fatty droplets 
as shown by Oil Red O Staining. These experiments supported the hypothesis that the high 
fat diet promotes the lipid accumulation and inflammation within the intima (Libby 2002; 
Hansson and Hermansson 2011). In response, oxidized lipids (oxLDLs) lead to activation 
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of endothelial cells, macrophages, and smooth muscle cells which consequently express 
vascular cell adhesion (VCAM-1) molecules (Iiyama, Hajra et al. 1999; Libby 2002; Chi 
and Melendez 2007). The inflammatory process together with the presence of oxidized 
LDLs might further enhance the phagocytic activity of intimal smooth muscle cells. It has 
been previously shown that smooth muscle cells possess similar scavenger receptors as 
macrophages, which recognize LDLs and contribute to foam cell creation (Schrijvers, De 
Meyer et al. 2007; Doran, Meller et al. 2008). The study within this thesis also found the 
accumulation of lipids in the intimal smooth muscle cells. Surprisingly, in the medial 
region fatty droplets were also detected. This could be associated with the inflammatory 
cascade within early lesions where the activated medial smooth muscle cells proliferate 
and change their phenotype from contractile to proinflammatory (Doran, Meller et al. 
2008; Boettger, Beetz et al. 2009). The enhanced activation of smooth muscle cells and 
their participation in the early plaque formation of 12 week old ApoE-/- mice was further 
demonstrated by the presence of collagen filaments in the intimal and medial 
atherosclerotic regions. In contrast to the young mice, 30 week old ApoE-/- mice, kept on a 
high fat diet for 26 weeks, represented the massive alteration and thickening process of the 
arterial wall associated with the expanded advanced plaques. The advanced lesions differed 
from the early fatty streaks of 12 week old ApoE-/- mice and were characterized by the 
presence of a formed fibrous cap where, besides activated endothelium and intimal smooth 
muscle cells, highly prevalent macrophage content was observed. All of the mentioned 
cells revealed strong phagocytic activity and lipid accumulation within the fibrous cap. 
Moreover the advanced plaques manifested the presence of a more complex necrotic core 
containing apoptotic cells and spindle smooth muscle cells. The necrotic core region within 
advanced plaques of 30 week old ApoE-/- mice revealed also fatty droplets. These regions 
with mostly distributed apoptotic cells usually lack the active phagocytic activity 
nevertheless, positive Oil Red O staining of the necrotic core could be explained by the 
fact that cholesterol, derived from overwhelmed intracellular macrophage storage, freely 
accumulated in extracellular space (Choudhury and Fisher 2009; Gui, Shimokado et al. 
2012). It has been also published that cell necrosis with increased quantities of 
extracellular lipids prompts further inflammation (Tabas 2005; Insull 2009). The 
histological assessment within this thesis demonstrated that a high fat diet, extensive 
immune cells’ recruitment and simultaneous cell apoptosis contributed to and changed 
completely the morphology of the aortic wall of 30 week old ApoE-/- mice. Highlighting 
the enormous changes within the atherosclerotic wall of 12 and 30 week old ApoE-/- mice, 
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these alterations would not have appeared without the upregulation of vascular cell 
adhesion (VCAM-1) molecules. The vast role of VCAM-1 molecules in atherosclerosis 
emerges via the α4β1 integrin binding motif, promoting the adhesion and capture of 
immune cells as monocytes and lymphocytes (Braun, Pietsch et al. 1999; Huo and Ley 
2001; Ley and Huo 2001; Libby 2006). Enhanced upregulation of VCAM-1 expression 
participates in the luminal leukocyte recruitment as well as in migration of immune cells 
into the plaques from adventitia regions (O'Brien, Allen et al. 1993; O'Brien, McDonald et 
al. 1996; Huo and Ley 2001). This study showed that VCAM-1 expression could be found 
in the atherosclerotic plaques of early and advanced lesions in the intimal as well as in the 
deeper regions of the formed lesions. The thesis findings demonstrated furthermore that 
VCAM-1 molecules co-localized within inflamed intimal endothelial as well as intimal 
smooth muscle cells and macrophages of 12 and 30 week old ApoE-/- mice. In addition to 
these findings, the strong VCAM-1 expression pattern was detected within the media and 
adventitia of the aortic wall where medial smooth muscle cells resided. The results 
presented in this thesis gave evidence that upregulation of VCAM-1 was continuously 
present in the inflammatory process within 12 and 30 week old ApoE-/- mice and thus 
disclosing that VCAM-1 expression is as equally important in the early as in the advanced 
plaque growth. The immune VCAM-1 staining of atherosclerotic aortae, presented in this 
work, also revealed the interesting observation that VCAM-1 was strongly expressed on 
macrophages and smooth muscle cells within the intima and media rather than on intimal 
endothelium of early and advanced plaques as also observed by O’Brien et al (O'Brien, 
Allen et al. 1993). The strong presence of smooth muscle cell VCAM-1 expression, 
stimulated by oxidized lipids and plaque cytokines, not only supports but confirms the 
influence of smooth muscle cells on leukocyte migration within early and advanced lesions 
(Libby and Li 1993; May, Neumann et al. 2000; Doran, Meller et al. 2008). Thus not only 
endothelial cells but also smooth muscle cells are engaged in the recruitment of leukocytes 
via VCAM-1 molecules (Braun, Pietsch et al. 1999). Additionally the observations of this 
thesis on plaque macrophage VCAM-1 expression could be explained by the fact that 
macrophages express VCAM-1 in response to produced cytokines during plaque formation 
(O'Brien, Allen et al. 1993; Iiyama, Hajra et al. 1999). While leukocytes’ adhesion and 
capture is associated with VCAM-1 expression, presented on intimal plaque cells, medial 
smooth muscle cells also express VCAM-1 molecules (Braun, Pietsch et al. 1999). The 
experiments of this thesis, including double staining of the smooth muscle cells and 
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VCAM-1, confirmed the co-localization of the medial smooth muscle cells with vascular 
cell adhesion molecules. 
 In summary, this thesis shows that VCAM-1 molecules appear to be one of the most 
important factors controlling the inflammatory process of atherosclerosis, and thus 
represent a compelling target for noninvasive visualization and its translation in clinical 
use. Owing to exceptional presence of VCAM-1 only upon the face of inflammation, 
targeting of these molecules would enable specific recognition and the evaluation of the 
extent of inflammation in atherosclerotic lesions. VCAM-1 molecules bear relation to 
involved immune cells, which leads to detrimental alterations within the arterial wall. 
Therefore this thesis focused firstly on the importance of biological background in order to 
depict the VCAM-1 expression within the early and advanced formed plaques. The 
evidence of presented work that VCAM-1 is extensively expressed within the intimal and 
medial cells of the atherosclerotic aortic wall influenced the decision of selecting VCAM-1 
as an excellent marker for monitoring the atherosclerotic lesions in the established murine 
atherosclerotic model. Thus targeting of VCAM-1 by a specific contrast agent could 
contribute to early detection and monitoring of the inflammatory process of 
atherosclerosis.    
 
5.2. USPIO conjugated to VCAM-1 cyclic peptide detects early and 
advanced lesions ex vivo 
 
Secondly, this thesis examined the feasibility of newly designed ultrasmall 
superparamagnetic iron oxide particles. As vascular cell adhesion molecules were 
extensively expressed on endothelial cells, macrophages, and smooth muscle cells within 
the intima and media of 12 and 30 week old ApoE-/- mice, the newly developed USPIO 
(P03011) iron oxide contrast agent, functionalized with VCAM-1 specific binding cyclic 
peptide, was utilized.  
 During the inflammatory process of atherosclerosis, the leukocyte ligand α4β1 binds 
to VCAM-1 receptors, and this interaction is crucial for leukocyte recruitment into 
atheroma-prone sites (Braun, Pietsch et al. 1999; May, Neumann et al. 2000; Huo and Ley 
2001; Ley and Huo 2001; Ley, Miller et al. 2011). Hence development of small peptides, 
based on α4β1 active sites, is promising for targeting and detection of vascular cell 
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adhesion molecules and could further contribute to the therapeutic strategies (You, Maxwell 
et al. 2002). The selected cyclic peptide, used in this thesis, represents similarity to the 
α4β1 complex and holds the potential to only bind to cells expressing VCAM-1 molecules 
(Patent number WO2004/058 275, US 2004/253181, Guerbet Research, France). As 
USPIO particles conjugated to specific VCAM-1 peptide were newly developed, this study 
firstly scrutinized the specificity and sensitivity of this targeted approach and conducted ex 
vivo experiments. 
 
5.2.1. Targeted USPIO particles represented high affinity for VCAM-1 molecules 
 
The USPIO particles and the VCAM-1 peptide was synthetized and validated by Guerbet 
Research Laboratory in France. As described in the patent number WO2004/058 275 (US 
2004/253181), the cyclic peptide Cys-Asn-Asn-Ser-Lys-Ser-His-Thr-Cys (C-NNSKSHT-
C), used for synthesis of the functionalized USPIO-VCAM-1 contrast agent, was selected 
through cloning procedure. This specific sequence C-NNSKSHT-C revealed the active 
sites of the α4β1 integrin complex and thus the highest affinity for VCAM-1 molecules 
(Patent WO2004/058 275, US 2004/253181, Guerbet Research, France). The occurrence 
of the particular amino acids in the cyclic peptide sequence such as serine (S), histidine 
(H), threonine (T), and lysine (K) held the potential for specific VCAM-1 binding. Within 
the peptide, serine (S), histidine (H), and threonine (T) are important for active binding, 
interaction and further coordination with the VCAM-1 receptor (Irie, Kamata et al. 1997; 
You, Maxwell et al. 2002; Burtea, Laurent et al. 2009). Moreover lysine (K) is responsible 
for stabilization of peptide binding within VCAM-1 (Irie, Kamata et al. 1997; You, 
Maxwell et al. 2002; Burtea, Laurent et al. 2009). In order to stabilize the complete 
peptide sequence, selected peptide was further modified into cyclic form (Krumpe and 
Mori 2006) and thus strengthening the specific VCAM-1 binding. The peptide sequence C-
NNSKSHT-C represented the high affinity for VCAM-1 in murine as well as in the human 
endothelial cells (Patent WO2004/058 275, US 2004/253181, Guerbet Research, France) 
which was an essential step for further intended synthesis of targeted USPIO-VCAM-1 
particles and their in vivo application.  
 The conjugation of the specific cyclic peptide to the surface of iron oxide 
nanoparticles needs to be implemented in a homogenous and controlled manner 
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(Delehanty, Boeneman et al. 2010). USPIO particles were conjugated to the cyclic VCAM-
1 peptide via carboxylate (RCOO-) group and gem-bisphosphonate compounds 
(CH(PO3H2)2)n that covered the USPIO particles. Such a conjugation allowed stable 
grafting of the VCAM-1 peptide and ensured the presence of the peptide active sites on the 
surface of the iron oxide nanoparticles (Patent WO2004/058 275, US 2004/253181, 
Guerbet Research, France). Electron microscopy analyses confirmed and demonstrated the 
homogenous distribution and sustained stability of the targeted USPIO-VCAM-1 particles. 
 Based on superparamagnetic characteristics of iron oxide contrast agents, the high 
relaxivity rate (r2) of targeted and non-targeted USPIO particles, demonstrated in ex vivo 
measurements in the 17.6 T MR system, assured significant T2 and T2* contrast related to 
the presence of iron oxide particles.  
 
5.2.2. Targeted USPIO particles improved pharmacokinetics and shortened half-life 
time   
 
Evaluation of pharmacokinetics and biodistribution of newly developed nanoparticles is 
relevant for potential in vivo application and visualization (Lee, Veiseh et al. 2010). The 
structure, particle size, and additional binding ligand influence the circulation time and the 
internalization of the contrast agent within the targeted tissue (Corot, Robert et al. 2006; 
Thorek, Chen et al. 2006; Lee, Veiseh et al. 2010; Weinstein, Varallyay et al. 2010). 
Therefore proper structure and target design may promote the passage of nanoparticles 
from the blood stream allowing nanoparticle binding and capture within targeted 
atherosclerotic plaques (Corot, Robert et al. 2006; Lee, Veiseh et al. 2010). Many of the 
non-targeted large size iron oxide particles lack the specificity and are promptly eliminated 
by the phagocytic cells localized in the spleen, bone marrow, lymph nodes, and liver, 
limiting in vivo application and further clinical use (Corot, Robert et al. 2006; Lee, Veiseh 
et al. 2010). Too short a circulation time hampers the access of large nanoparticles to attain 
atherosclerotic plaques. Therefore small size iron oxide particles such as USPIOs are a 
better approach to reach atherosclerotic plaques and have a longer half-life time (Kooi, 
Cappendijk et al. 2003; Corot, Robert et al. 2006; Tang, Muller et al. 2009). 
 Prior to the ex vivo and in vivo imaging procedure, the pharmacokinetic and 
biodistribution studies of targeted USPIO-VCAM-1 (P03011) as well as non-targeted 
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USPIO (P3007) particles were conducted in order to evaluate the influence of iron coating 
and VCAM-1 binding peptide on particle half-life time and to explore the best optimal 
imaging time in the murine model. The pharmacokinetic analyses of targeted USPIO-
VCAM-1 particles enabled the assessment of the half-life time that ranged between 4±2.4 
hours in atherosclerotic ApoE-/- mice. Compared to healthy control C57Bl/6 mice, where 
the calculated half-life time of non- and targeted particles was almost exactly equal to 
about 6 hours, USPIO-VCAM-1 particles resulted in a shorter half-life time in 
atherosclerotic mice. On the contrary, the calculated half-life time of non-targeted USPIO 
revealed an extended circulation time of 6 hours in ApoE-/- mice which could be explained 
by the fact that USPIO did not possess the specific peptide attachment. Additionally it 
could be associated with the USPIO surface modification by polyethylene glycol (PEG) 
which prolonged the retention of the nanoparticles in the blood stream (Laurent, Forge et 
al. 2008; Lee, Veiseh et al. 2010). However both non-targeted USPIO as well as targeted 
USPIO-VCAM-1 particles possessed the PEG coating and due to this the prolonged half-
life time of USPIO particles could be entailed by the lack of specific peptide binding. 
These pharmacokinetic analyses helped to make an initial conclusion that surface 
modification by the conjugation process of cyclic VCAM-1 peptide to USPIO particles 
could bear the advantage over the non-specific USPIO binding and thus shorten the half-
life time of USPIO-VCAM-1 particles. The shorter circulation time of targeted iron 
particles could be also related to a controlled passage of nanoparticles to the specific cells 
expressing VCAM-1 within atherosclerotic lesions (Delehanty, Boeneman et al. 2010). 
Owing to the knowledge of the nanoparticles’ clearance and half-life time, the optimal in 
vivo imaging time was defined. The assessment of half-life time of USPIO-VCAM-1 and 
USPIO was mandatory to image specifically iron particles within atherosclerotic lesions, 
ruling out the artifacts derived from unspecific binding or still circulating particles in the 
blood stream.  
 The concentration of injected USPIO-VCAM-1 as well as USPIO nanoparticles 
analyzed within 24 hours reverted mostly into the basic level in the serum. These findings 
allowed verification of the optimal ex vivo and in vivo imaging time point which matched 
with the biodistribution studies pointing to the huge elimination of biocompatible small 
USPIO nanoparticles through the phagocytic cells in the liver and spleen during that time 
point. Besides the distribution of USPIO-VCAM-1 within the macrophages, recognized as 
Kupffer cells of the liver and within the macrophages of splenic red pulp, kidneys and 
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lymph nodes were positively stained for USPIO-VCAM-1 particles and due to that they 
appeared to participate in the iron elimination. Additionally, the presence of USPIO-
VCAM-1 particles in the subcapsular sinus region of the lymph nodes and in the cortex 
and medulla region of the kidneys could be associated with the enhanced atherosclerotic 
inflammatory process and the appearance of immune cells expressing VCAM-1 within 
these organs. 
 Murine models of atherosclerosis are beneficial for experimental work and provide 
valuable information about the pathophysiological occurrence of this disease (Daugherty 
2002; Zaragoza, Gomez-Guerrero et al. 2011; Getz and Reardon 2012). However it is 
important to remember that the laboratory conditions are not always equal to those found 
in humans. Pharmacokinetic analyses and half-life time of particles used in the mouse 
atherosclerotic model could differ completely when applied to humans. Therefore human 
studies including pharmacokinetics, biodistribution, and assessment of toxicity are 
mandatory to evaluate potential particle use for future in vivo clinical translation.  
 
5.2.3. Targeted USPIO particles allowed ex vivo detection of early and advanced 
atherosclerotic lesions 
 
An initial ex vivo MR dose-dependent validation studies on agar phantoms containing 
excised atherosclerotic aortae of USPIO-VCAM-1 and USPIO injected ApoE-/- mice, 
demonstrated the feasibility of targeted particles and further enabled verification of the 
optimal injection dose for detecting atherosclerotic plaques. The 600 µmol/kg dose of 
injected USPIO-VCAM-1 particles was evaluated to produce significant signal loss 
(blooming effect) within atherosclerotic areas and to show the best T2/T2* contrast. The 
600 µmol/kg dose of injected USPIO particles also caused signal loss within 
atherosclerotic root regions, however the signal loss was unostentatious when confronted 
with applied targeted USPIO-VCAM-1 particles. These initial findings emphasized that a 
600 µmol/kg dose of USPIO-VCAM-1 contrast agent successfully marked ex vivo 
atherosclerotic plaques, pointing to its potential for further in vivo application. On the 
contrary, equal doses of USPIO particles were not sufficient to create the same significant 
T2 effect, as it was revealed in T2-weighted images of agar phantoms from ApoE-/- mice 
injected with USPIO-VCAM-1. Further these ex vivo experiments indicated that 
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application of specific USPIO-VCAM-1 particles enables a reduction of the injection dose 
almost by half in comparison to previous studies on visualization of atherosclerosis, where 
the dose of 1000 µmol/kg USPIOs was utilized in murine mouse model (Morris, Olzinski 
et al. 2008; Klug, Kampf et al. 2009; Sigovan, Bessaad et al. 2010). 
 Applied USPIO-VCAM-1 and USPIO particles (600 µmol/kg dose) were analyzed 
ex vivo and in vivo pre and 24 hours post injection to follow the pharmacokinetic data. 
According to the pharmacokinetics, concentration of 600 µmol/kg USPIO-VCAM-1 as 
well as USPIO nanoparticles had mostly cleared from the blood stream within 24 hours. As 
a result of the initial preliminary experiments, 24 hours imaging time point was considered 
as optimal for subsequent ex vivo and in vivo imaging in the mouse model. Given a 
USPIO-VCAM-1 half-life time of 4±2.4 hours and almost complete particle clearance, ex 
vivo and in vivo imaging was performed 24 hours post USPIO-VCAM-1 injection, 
allowing the specific detection of internalized contrast agents within atherosclerotic 
plaques and excluding unspecific artifacts generated by circulating particles near to the 
vessel wall.  
 Ex vivo MR experiments of aortae placed in agar from 12 and 30 week old ApoE-/- 
mice injected with dose of 600 µmol/kg USPIO-VCAM-1 particles revealed strong signal 
loss within aortic root regions. These observations are in line with preliminary ex vivo 
dose-dependent studies which confirm significant detection of USPIO-VCAM-1 particles 
within atherosclerotic lesions in comparison to non-significant results from non-targeted 
USPIO injected 12 and 30 week old ApoE-/- mice. Ex vivo MR data of early and advanced 
lesions provided further information about the thickening process within the aortic wall of 
atherosclerotic mice which were kept on the high fat diet over time. T2-weighted MR 
images also indicate that the observed signal loss within the early and advanced plaques of 
USPIO-VCAM-1 injected ApoE-/- mice correlate with the thickening process of the aortic 
wall. Signal loss associated with applied USPIO-VCAM-1 particles was broadly magnified 
within the advanced lesions of 30 week old ApoE-/- mice and only partially within early 
lesions of 12 week old ApoE-/- mice. USPIO-VCAM-1 particles were identified as dark 
areas in the intima but also in the media of early and advanced atherosclerotic plaques. 
Histological staining confirmed further the VCAM-1 expression within the intimal and 
medial region of early and advanced atherosclerotic plaques where the signal loss areas of 
USPIO-VCAM-1 particles were found.  
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 In summary, these findings of the thesis do point out that targeted USPIO-VCAM-1 
particles enable a specific detection of early and advanced plaques and can be utilized to 
monitor the inflammatory process at discrete time points ex vivo. 
 
5.3. USPIO conjugated to VCAM-1 cyclic peptide detects early and 
advanced lesions in vivo and monitors inflammation 
 
The preliminary studies on USPIO-VCAM-1 efficiency demonstrated a homogenous 
particle distribution, sustained stability, biocompatibility, sufficient clearance, and good 
T2/T2* contrast. USPIO conjugation to the specific VCAM-1 binding peptide contributed 
to sensitive and specific detection of atherosclerotic lesions ex vivo in comparison to a low 
nonspecific USPIO particle uptake. These preliminary experiments are fundamental for 
further in vivo application.   
 Intravenous administration of targeted USPIO-VCAM-1 and non-targeted USPIO 
particles into control C57Bl/6 and atherosclerotic ApoE-/- mice revealed the same findings 
as the pharmacokinetic data and ex vivo MRI, pointing to the optimal imaging time 
appearing within 24 hours. The acquired preliminary in vivo MR images at 1 hour and 6 
hours illustrate difficulties in obtaining clear images with high signal to noise ratios. At a 
calculated half-life time of 4 to 7 hours for USPIO-VCAM-1 and USPIO, the contrast 
agent was still in the blood and therefore produced artifacts generated by circulating 
particles in the vicinity of the vessel wall. As blood flow is rapid in the center of the aorta, 
but slow within the vessel wall, it is likely to be very challenging to clearly distinguish 
signal loss from the contrast agent capture in the atherosclerotic lesions from signals, 
which originate from iron particles circulating near to the vessel wall. This explains clearly 
the occurrence of in vivo MRI pre and 24 hours post USPIO-VCAM-1 or USPIO 
application in the control C57Bl/6 and ApoE-/- mice.   
 MR imaging of control and ApoE-/- mice was approached at 17.6 T MR System. Such 
a system with a high magnetic field and strong gradients contributes to and allows imaging 
of small aortic vessels with high spatial resolution. As the T2*-weighted imaging was 
proposed to be optimal for the sensitive detection of iron oxide nanoparticles (Corot, 
Robert et al. 2006; Tang, Muller et al. 2009), a FLASH sequence with a very short echo 
time of 1 millisecond was used for the imaging. The alterations of signal intensity within 
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the aortic root pre and 24 hours post USPIO-VCAM-1 or USPIO injection were presented 
on T2*-weighted MR images. To avoid susceptibility artifacts that might influence the 
T2*, a shimming protocol, a short time of acquisition and an ECG triggering was applied 
and contributes to the high signal to noise ratio images excluding motion artifacts. In 
addition, application of a very short echo time of 1 millisecond further reduced artifacts 
derived from the chemical shift from water-fat face. The implemented shim protocol, short 
echo time, fat saturation, and the triggering by ECG prevented image disturbance 
elucidating only an increase in signal loss in association with applied iron particles within 
the aortic wall. The in vivo findings were also corroborated by ex vivo 3D MSME 
visualization of the aortic root regions, where a magnified increase in signal loss and decay 
in T2 time of USPIO-VCAM-1-injected ApoE-/- mice was presented.  
 In the present study, the application of 600 µmol/kg USPIO-VCAM-1 particles 
revealed significant signal loss within the aortic root of early and advanced lesions. T2*-
weighted MR images of the aortic wall of 12 week old ApoE-/- mice, kept on a high fat diet 
for 8 weeks, demonstrated visible partial darkening within early lesions associated with 
application of USPIO-VCAM-1 particles. A further USPIO-VCAM-1 injection in 30 week 
old ApoE-/- mice, kept on a high fat diet for 26 weeks, exhibited very strong darkening 
within the whole atherosclerotic aortic wall. These findings were in line with the ex vivo 
MR data and the histological staining of VCAM-1 expression. Ex vivo high resolved T2-
weighted MR images confirmed similarly, that partial signal loss occurred within the early 
lesions of 12 week old ApoE-/- mice, as indicated by T2*-weighted in vivo MRI. 
Histological staining of VCAM-1 expression showed the presence of VCAM-1 molecules 
in the regions of the observed partial signal loss caused by USPIO-VCAM-1 particles. In 
contrast, administration of 600 µmol/kg USPIO particles had no influence and no effect on 
determination of early plaques in vivo. The ex vivo and in vivo MR results of USPIO-
VCAM-1 treated 30 week old ApoE-/- correlated well. Ex vivo T2- and in vivo T2*-
weighted MR images showed that the strong broad signal loss occurred within advanced 
lesions of 30 week old ApoE-/-. The strong signal drop within the aortic wall of advanced 
plaques corresponded further to intense VCAM-1 expression. The ex vivo and in vivo MR 
experiments of USPIO-VCAM-1 injected mice visualized the atherosclerotic alterations of 
12 and 30 week old ApoE-/- mice, thus elucidating that application of targeted USPIO-
VCAM-1 particles could help to early recognize atherosclerotic changes and monitor the 
inflammatory process at different time points in vivo.  
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 The signal loss caused by iron oxide deposits found on T2*-weighted FLASH MR 
images was semi-quantified and presented as a signal to noise ratio (SNR) and contrast to 
noise ratio (CNR) value. These data represented the signal variations within the aortic wall 
pre- and post-USPIO-VCAM-1, and USPIO contrast agent administration. The calculation 
of the SNR values relied only on the measured signal intensities (SI) within the aortic root 
pre and post contrast agent administration, and was demonstrated as the decreased SNR 
due to the signal loss associated with the iron oxide deposition within the aortic vessel. The 
calculated CNR values were based on signal distinction between the blood, which was 
defined as internal signal reference, and the aortic root, but in addition were standardized 
and corrected to the noise of the image (Klug, Kampf et al. 2009; Michalska, Machtoub et 
al. 2012). As the signal intensity of blood pre and post iron oxide contrast agent was 
proposed as internal reference, a total elimination of particles from the blood was also 
substantial for the calculation of the contrast to noise ratio (CNR). On the contrary, SNR 
values were not based on an internal signal reference and therefore the results on calculated 
SNR could be affected by variations in the signal intensities caused by experiments 
executed on different days or changing the mouse position within the coil. Thus the CNR 
provided valuable additional information to the SNR values and corrected for differences 
in the signal intensity pre and post iron oxide particles injection. Calculated SNR values of 
ApoE-/- fed a high fat diet for 8 and 26 week resulted in a significant signal decline post 
USPIO-VCAM-1 application. The same magnified findings were observed with the 
assessed CNR values of young and advanced atherosclerotic ApoE-/- mice treated with 
USPIO-VCAM-1 particles. These results of SNR and CNR of 12 and 30 week old ApoE-/- 
mice confirmed the significant signal intensity alterations within the aortic root associated 
with USPIO-VCAM-1 injection. Compared to the significance of USPIO-VCAM-1 
particles in detection of early and advanced atherosclerotic plaques, USPIO injection 
within 12 and 30 week old atherosclerotic ApoE-/- mice had no remarkable effect on signal 
intensity alterations. In 12 week old ApoE-/- mice, there were no signal intensity change of 
the SNR and CNR values pre and post USPIO injection. In 30 week old ApoE-/- mice, the 
calculated SNR and CNR values showed minimal and non-significant signal intensity 
alteration within the aortic wall after USPIO injections. Hence the semi-quantification, 
reflected by SNR and CNR values, confirmed the success of USPIO-VCAM-1 in vivo 
imaging of atherosclerotic plaques.  
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    Using an ultra-high field MRI, this work enabled USPIO-VCAM-1 visualization 
within early and advanced atherosclerotic plaques. It was unlikely to mark the 
atherosclerotic lesions with non-targeted USPIOs using the same 600 µmol/kg injection 
dose, preparation, equal MR sequences, and imaging time as represented with applied 
targeted USPIO-VCAM-1 particles. Previously published studies however have shown 
macrophage uptake of non-targeted USPIO contrast agent and MRI visualization of 
advanced atherosclerotic plaques in murine models (Morris, Olzinski et al. 2008; Klug, 
Kampf et al. 2009; Sigovan, Bessaad et al. 2010) and hyperlipidemic rabbits (Ruehm, 
Corot et al. 2001; Sigovan, Boussel et al. 2009) . USPIO particles have also been utilized 
in order to image human carotid lesions (Kooi, Cappendijk et al. 2003; Trivedi, JM et al. 
2004). All of these studies have used USPIO particles that possessed a dextran coating, 
which might explain the deposition of USPIO contrast agent within the plaques. In contrast 
to previous studies on dextran USPIO plaque deposition, gem-bisphosphonate coated 
USPIO, used in this study, allowed only marginal detection of signal within advanced 
plaques, but not the early lesions. The reason for non-significant and weak signal intensity 
loss could be associated with gem-bisphosphonate coating of USPIOs injected 30 week old 
ApoE-/- mice. Further it could be explained by the fact that the dose of only 600 µmol/kg 
iron particles was utilized in this work, which differed from the 1000 µmol/kg doses of 
previous studies on dextran USPIOs. This illuminates that the cellular non-targeted USPIO 
approach requires a very high injection dose in order to visualize the plaques. This 
emphasizes the specificity and potential of the targeted USPIO-VCAM-1 particles.  
 There have been earlier studies that have approached VCAM-1 molecules for 
imaging of atherosclerosis. Former investigations have utilized antibodies as a binding 
ligand coupled to microbubbles and detected by ultrasound ex vivo (Kaufmann, Sanders et 
al. 2007; Ferrante, Pickard et al. 2009). Another work has demonstrated MR imaging of 
VCAM-1 molecules by antibodies and linear peptide attached to iron oxide particles 
(Kelly, Nahrendorf et al. 2006; Nahrendorf, Jaffer et al. 2006; McAteer, Schneider et al. 
2008). There were also studies using perfluorocarbon for VCAM-1 detection presented by 
19F magnetic resonance (Southworth, Kaneda et al. 2009). Nuclear imaging has also 
targeted VCAM-1 molecules with fluorine (Nahrendorf, Keliher et al. 2009) or 
radiolabeled with technetium (Broisat, Hernot et al. 2012). These studies have used the 
VCAM-1 approach. However, they differed from this work. For instance, Kelly et al 
(Kelly, Nahrendorf et al. 2006) and Nahrendorf et al (Nahrendorf, Jaffer et al. 2006), 
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utilized linear peptide sequence VHPKQHR (VINP 28) conjugated to CLIO iron oxide 
particles to facilitate ex vivo and in vivo visualization of VCAM-1 molecules within 
atherosclerotic plaques by MRI. Further the identical linear peptide sequence VHPKQHR 
functionalized with fluorine 18F was synthetized and used for VCAM-1 detection of 
atherosclerotic lesions by PET-CT approach (Nahrendorf, Keliher et al. 2009). The 
purpose of linear peptide VHPKQHR was expanded and another group exploited this 
linear peptide conjugated to perfluorocarbon in order to image renal inflammatory process 
in ApoE-/- mice by ex vivo MRI (Southworth, Kaneda et al. 2009). Besides elaborated 
linear peptide use, there have been also studies demonstrating ultrasound detection of 
atherosclerotic plaques by VCAM-1 antibody linked to microbubbles in ex vivo and in vivo 
ApoE-/- mice (Kaufmann, Sanders et al. 2007; Ferrante, Pickard et al. 2009). In addition to 
the above presented work, there were also studies on double targeted iron oxide particles 
particularly MPIO linked to antibodies against P-Selectins and VCAM-1. That approach 
enabled luminal depiction of adhesion molecules by ex vivo MRI of atherosclerotic aortae 
from ApoE-/- mice (McAteer, Schneider et al. 2008). Recently, another group presented 
concept of nanobodies radiolabeled with technetium for detection of inflamed plaques in 
ApoE-/- mice (Broisat, Hernot et al. 2012). Nevertheless, none of the aforementioned 
studies employed the USPIO-VCAM-1 contrast agent utilized in this thesis. 
 In this thesis, a USPIO particle with gem-bisphosphonate coating and the specific 
cyclic VCAM-1 peptide (Patent number WO2004/058 275/ US 2004/253181, Guerbet 
Research France) differed for instance from the functionalized VINP28 contrast agent 
utilized by Kelly et al and Nahrendorf et al (Kelly, Nahrendorf et al. 2006; Nahrendorf, 
Jaffer et al. 2006). The disparity of USPIO-VCAM-1 particles, used in this work, 
compared to previously developed VINP28, was based on different particle size, coating, 
and specific VCAM-1 peptide sequence. Due to these differences, the cyclic peptide 
conjugated to USPIO particles (P03011) was cleared from the blood stream within a short 
period of time, terminating in a half-life time of 4.0±2.4 hours after administration in 
ApoE-/- mice, while VINP28 circulated for 17.7 hours (Nahrendorf, Jaffer et al. 2006). The 
experiments, within this thesis, concentrated on the visualization of the aortic root region 
in ApoE-/- mice fed a high fat diet at various time points. Further in vivo high resolution 
MRI was conducted 24 hours post USPIO-VCAM-1 application. A half life time of 
USPIO-VCAM-1 of 4±2.4 hours allowed the imaging time at 24 hours after USPIO-
VCAM-1 injection, when iron particles were completely eliminated from the circulation, 
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enabling the specific detection of the internalized USPIO-VCAM-1, withdrawing 
unspecific artifacts originated from circulating particles next to the vessel wall. Use of an 
ultra-high field MRI system allowed high resolution imaging and identification of 
inflammation within small sized plaques. Therefore, this work could visualize the specific 
cyclic USPIO-VCAM-1 particles within the early and advanced atherosclerotic lesions in 
ApoE-/- mice ex vivo and in vivo.  
 
5.4. USPIO conjugated to VCAM-1 cyclic peptide localizes within the 
plaque cells expressing VCAM-1 
 
Investigation of the cellular localization of the USPIO-VCAM-1 contrast agent within the 
aortic root region, demonstrated by Prussian Blue staining, revealed iron particles in early 
and advanced atherosclerotic lesions of USPIO-VCAM-1 injected ApoE-/- mice but not in 
control C57Bl/6 mice. The deposition of iron particles was found within intimal 
endothelial, smooth muscle cells, and macrophages. Modest accumulation of USPIO-
VCAM-1 particles was also detected within the border to the medial areas. In addition to 
those observations, these plaque cells presented very strong VCAM-1 expression. Thus it 
indicated the specificity of USPIO-VCAM-1 binding to the cells expressing VCAM-1 
molecules. Nevertheless, low sensitivity of the Prussian Blue technique was noticed and 
due to that only iron particles that accumulated in larger numbers could be detected. 
Therefore electron microscopy was also performed. Using this technique, for the first time 
iron particles were identified not only in the lumen of the plaque and deeper in the intima 
but also in the medial regions. With this modality, it was further possible to exactly define 
the deposition of iron particles found in the intracellular luminal endothelial cells within 
endosomes. Next, the iron particle deposits were observed within the extracellular matrix 
between the intimal smooth muscle and endothelial cells. In addition iron particles were 
found on the outer surface of smooth muscle cells and in the medial region where the 
collagen filaments and medial smooth muscle cells occurred. Compared with histology, the 
medial region was also positively stained for VCAM-1 demonstrating the specificity of 
USPIO-VCAM-1 binding not only in the intima region but also in the media where smooth 
muscle cells expressed VCAM-1. This corroborated the results that USPIO-VCAM-1 
particles explicitly targeted cells expressing VCAM-1 molecules within early and 
107 
 
advanced plaques and provided further the essential information about the luminal and 
medial cell contribution in the plaque formation in murine models of atherosclerosis.   
 The nonspecific uptake of USPIO might be present within endothelial cells and 
macrophages (Ruehm, Corot et al. 2001; Kooi, Cappendijk et al. 2003; Morris, Olzinski et 
al. 2008). This work also detected minimal nonspecific signal loss, related to USPIO 
application, within the aortic root region of 30 weeks old ApoE-/- mice. Nevertheless the 
signal loss was irrelevant when compared to the group of ApoE-/- mice injected with 
USPIO-VCAM-1 particles. Including positive iron staining of atherosclerotic lesions of 
USPIO-VCAM-1 injected ApoE-/- mice, from these observations, high specificity of 
targeted iron particles beyond non-targeted USPIO uptake emerged. 
 Using a combination of histology and electron microscopy, this study could 
specifically point to distribution of functionalized USPIO-VCAM-1 particles within early 
and advanced atherosclerotic process. This work could further localize for the first time 
functionalized iron particles not only in luminal region of the plaque but also in deeper 
plaque areas where medial smooth muscle cells resided in early and advanced lesions.  
 
5.5. Clinical consideration of USPIO-VCAM-1 versus USPIO application  
 
Although there have been successful previous clinical studies on non-targeted USPIO 
particles termed as Ferumoxtran-10 (Sinerem, Guerbet) for imaging of macrophage uptake 
in advanced and prone to rupture carotid plaques of human patients, this non-targeted 
approach has revealed some limitations in clinical practice (Kooi, Cappendijk et al. 2003; 
Tang, Muller et al. 2009). The main problem referred to the half-life time of Ferumoxtran-
10 (Sinerem), which was equated to 24 to 36 hours (Tang, Muller et al. 2009). This 
circulation time was considered too long for visualizing macrophages in human plaques. 
Another issue regarding the use of USPIO particles in clinics was related to MR imaging 
pre and post iron oxide application. However the pre and post imaging procedure is needed 
to distinguish the signal loss associated with applied iron particles from the blood 
degradation products that might appear on acquired images (Kooi, Cappendijk et al. 2003; 
Tang, Muller et al. 2009). Moreover imaging with non-targeted USPIO particles has 
demonstrated only advanced and prone to rupture carotid human plaques, which in terms 
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of clinical use, could be a limitation. USPIO particles, confined to recognition of advanced 
plaques, did not allow early plaque detection. Due to that the functionalized USPIO-
VCAM-1 particles could be a better approach allowing specific target-oriented detection of 
early and advanced plaques. 
 
5.6. Conclusion and perspectives of USPIO-VCAM-1 application 
 
This thesis presented the potential of specific USPIO conjugated to the VCAM-1 binding 
peptide over unspecific USPIOs for preclinical application and evaluation of 
atherosclerosis. It firstly demonstrated that selection of VCAM-1 molecules offers a good 
and potential strategy for imaging of atherosclerosis, as these vascular cell adhesion 
molecules play an explicit role in the early phase of inflammation and are also 
continuously up-regulated within the advanced plaque in the murine models as well as in 
humans (Davies, Gordon et al. 1993; O'Brien, Allen et al. 1993; Ley and Huo 2001). 
Secondly, this thesis showed the capability of the newly designed USPIO contrast agent 
conjugated to the specific cyclic peptide for VCAM-1 recognition. The experimental 
studies including ultra-high field MRI, histology, and electron microscopy enabled further 
ex vivo and in vivo detection of applied USPIO-VCAM-1 particles within the aortic root 
region of early and advanced atherosclerotic plaques of 12 and 30 week old ApoE-/- mice. 
Hence functionalized USPIO particles targeting VCAM-1 molecules allow specific and 
sensitive detection of early and advanced plaques at the molecular level, giving the new 
possibilities for early detection of atherosclerotic plaques. Therefore the use of a 
functionalized contrast agent could also offer promising method for clinical evaluation of 
early atherosclerotic alterations. However besides advantages, these functionalized 
particles also have some limitations. One drawback of the USPIO-VCAM-1 contrast agent 
is the still long circulation time of 4±2.4 hours, which hampers the allowance of pre and 
post contrast MR imaging within narrow intervals without changing the position of the 
patients inside the coil. A relatively short half-life time of the contrast agent is mandatory 
for one stop acquisition MRI to rule out undesired background signals from circulating 
nanoparticles during the measurement and to prevent possible toxic effects. To consider 
this targeted approach with USPIO-VCAM-1 particles for a human application, the particle 
design needs to be improved further to shorten half-life time, allowing sensitive detection 
within atherosclerotic plaques at low administration doses. 
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 This thesis demonstrated a semi-quantification approach to the signal loss associated 
with iron oxide deposits within atherosclerotic root regions. The great opportunity to 
visualize plaque is realized by specially designed sequences that would transform the 
signal loss, derived from applied iron oxide particles, allowing further quantification of the 
exact iron particle amount in post-processing step. Such sequences would accurately 
highlight the location of iron oxide particles within the plaque regions without any further 
confirmation by ex vivo histology, also enabling subtraction of the signal differences 
related to iron particles from artifacts that might presumably occur (Dahnke, Liu et al. 
2008). 
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